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Neutralizing antibodies (NAbs) are effective in treating COVID-19 but the mechanism of immune 47 
protection is not fully understood. Here, we applied live bioluminescence imaging (BLI) to monitor 48 
the real-time effects of NAb treatment in prophylaxis and therapy of K18-hACE2 mice intranasally 49 
infected with SARS-CoV-2-nanoluciferase. We visualized sequential spread of virus from the 50 
nasal cavity to the lungs followed by systemic spread to various organs including the brain, 51 
culminating in death. Highly potent NAbs from a COVID-19 convalescent subject prevented, and 52 
also effectively resolved, established infection when administered within three days of infection. 53 
In addition to direct neutralization, in vivo efficacy required Fc effector functions of NAbs, with 54 
contributions from monocytes, neutrophils and natural killer cells, to dampen inflammatory 55 
responses and limit immunopathology. Thus, our study highlights the requirement of both Fab 56 
and Fc effector functions for an optimal in vivo efficacy afforded by NAbs against SARS-CoV-2. 57 
 58 
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SARS-CoV-2-neutralizing monoclonal antibodies (NAbs) are an attractive countermeasure for 63 
both COVID-19 prevention and therapy (Schafer et al., 2021; Voss et al., 2020; Weinreich et al., 64 
2021). To date, multiple NAbs against the spike (S) glycoprotein of SARS-CoV-2 have been 65 
identified from convalescent subjects. The majority of NAbs bind to the receptor binding domain 66 
(RBD) in the S1 subunit for inhibiting virus attachment to the human Angiotensin Converting 67 
Enzyme 2 (hACE2) receptor. NAbs against the N-terminal domain (NTD) of S1 as well as the S2 68 
subunit have also been isolated (Anand et al., 2021b; Liu et al., 2020; Voss et al., 2020). NAbs 69 
have demonstrated varying levels of efficacy and protection in multiple animal models of SARS-70 
CoV-2 (Alsoussi et al., 2020; Baum et al., 2020; Fagre et al., 2020; Hansen et al., 2020; Hassan 71 
et al., 2020; Li et al., 2020; Rogers et al., 2020; Shi et al., 2020b; Winkler et al., 2020; Zost et al., 72 
2020a; Zost et al., 2020b). However, the in vitro neutralization potency of NAbs has not 73 
consistently correlated with in vivo protection (Bournazos et al., 2014; Schafer et al., 2021). While 74 
the antigen binding domain (Fab) of antibodies are critical for neutralization, the fragment 75 
crystallizable (Fc) domain can contribute significantly to their in vivo efficacy (Bournazos et al., 76 
2019; Bournazos et al., 2014; DiLillo et al., 2014). Fc engagement of Fc gamma receptors (FcγRs) 77 
can elicit complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity 78 
(ADCC) and antibody-dependent cellular phagocytosis (ADCP). The Fc region can recruit natural 79 
killer (NK) cells, monocytes, or neutrophils that can facilitate clearance of infected cells and shape 80 
the cytokine response produced by these cells for enhancing adaptive and cell-mediated immune 81 
responses (Lu et al., 2018). Fc effector functions can also be detrimental to the host, especially 82 
against respiratory diseases such as respiratory syncytial virus (RSV) and SARS-CoV-1 leading 83 
to antibody-dependent enhancement (ADE) and aggravated disease pathology (Bolles et al., 84 
2011; Halstead and Katzelnick, 2020; Ruckwardt et al., 2019). Therefore, a careful investigation 85 
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NAb mechanisms that elicit protective or pathological consequences is required before their 86 
clinical deployment. 87 
Animal models evaluated to date (Johansen et al., 2020; Leist et al., 2020a; Leist et al., 88 
2020b) have not fully recapitulated pathological features of human COVID-19. Transgenic mice 89 
expressing hACE2 under the cytokeratin 18 promoter (K18-hACE2 mice) however, have some 90 
distinct advantages. Primarily, they are permissive and highly susceptible to human-tropic SARS-91 
CoV-2 virus strains and succumb to infection within a week (McCray et al., 2007; Shi et al., 2020a; 92 
Winkler et al., 2020). This allows for a rapid turnaround and a high bar for identifying effective 93 
prophylactic or therapeutic intervention strategies. In susceptible humans, SARS-CoV-2 infection 94 
disables innate immunity and elicits an imbalanced inflammatory cytokine response in the lungs 95 
leading to acute respiratory distress syndrome (ARDS) which is the major cause of death 96 
(Graham and Baric, 2020). Lethality in K18-hACE2 mice was initially associated with lung 97 
inflammation, cytokine storm and impaired respiratory function (Winkler et al., 2020). However, it 98 
has recently been recognized that the pathogenic endpoint in K18-hACE2 mice is a result of viral 99 
neuroinvasion and an ensuing neuronal disease (Carossino et al., 2021; Golden et al., 2020; Leist 100 
et al., 2020a). Infact, many patients display a myriad of neurological symptoms during and after 101 
recovery from SARS-CoV-2 infection (Ellul et al., 2020). Finally, mouse FcγRs display similar 102 
affinities to human antibodies (Dekkers et al., 2017). Therefore, K18-hACE2 mice serve as 103 
excellent models for evaluating and screening candidate human NAbs for their effects on SARS-104 
CoV-2 replication and pathogenesis.  105 
Bioluminescence imaging (BLI)-guided studies permit live visualization of pathogen 106 
spread to diverse anatomical site, the identification of relevant tissues of interest and a real-time 107 
readout of treatment regimens accelerating the evaluation process. A BLI-driven platform has not 108 
been harnessed for studying infectious respiratory pathogens like SARS-CoV-2 that require level 109 
3 biosafety containment. Here, we have established a BLI-driven approach to study SARS-CoV-110 
2 infection with a well characterized replication competent virus carrying a nanoluciferase (nLuc) 111 
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reporter in the place of the Orf7A gene (Xie et al., 2020a; Xie et al., 2020b). SARS-CoV-2-nLuc 112 
closely mimics the wildtype virus replication kinetics and stably maintains the nLuc reporter over 113 
five generations in vitro. In addition, Orf7a deletion was recently shown to induce comparable 114 
pathology to the wild-type virus (Silvas et al., 2021). Our in vivo imaging studies revealed that the 115 
virus spreads from the nasal cavity to lungs for establishing infection. This was followed by 116 
infection of cervical lymph nodes (cLNs), brain, and systemic dissemination. Once neuroinvasion 117 
occurred, the virus replicated rapidly in the brain leading to fulminant infection and death by 6-7 118 
days post infection (dpi). A single prophylactic intraperitoneal (i.p.) administration of highly potent 119 
NAbs isolated from a convalescent COVID-19 subject completely prevented SARS-CoV-2 120 
infection and mortality in K18-hACE2 mice. Protection was associated with widespread 121 
localization of administered NAbs and Fc-mediated effector functions with contributions from 122 
monocytes and NK cells as well as reduced induction of inflammatory cytokines. BLI also revealed 123 
a therapeutic window of 3 dpi for NAb for successfully halting progression of established infection 124 
in the lungs as well as to distal tissues. Thus, our BLI-driven study highlighted the requirement for 125 
both neutralizing and Fc effector functions of NAbs to elicit optimal virological and immunological 126 
outcome against SARS-CoV-2. 127 
 128 
Results 129 
BLI allows Visualization of SARS-CoV-2 Replication Dynamics and Pathogenesis  130 
We tracked spread of SARS-CoV-2-nLuc using BLI after intranasal (i.n.) challenge in K18-hACE2 131 
mice (Figure 1A). 1 x 105 FFU of SARS-CoV-2 generated sufficient photon flux to allow non-132 
invasive BLI. Importantly, luciferase signal was absent in C57BL/6J (B6) mice lacking hACE2 133 
(Figure 1B). Temporal tracking of emitted light intensities revealed that the virus replicated in the 134 
nasal cavity in a biphasic manner (Figure 1C). Luminescent signal in the nose increased in the 135 
first two days of infection after which it diminished before increasing again between 5 to 6 dpi 136 
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when systemic spread occurred. The first signs of infection in the lungs were observed at 1 dpi. 137 
The nLuc signal then steadily increased in the lungs until 3 dpi and plateaued thereafter. We 138 
detected nLuc signals in the cLNs and brain region (imaging in ventral position) at 4 dpi. There 139 
was a steep rise in nLuc activity in the brain from 4 to 6 dpi indicating neuroinvasion and robust 140 
virus replication (Figure 1B, C, Video S1). This was accompanied by widespread replication of 141 
the virus in the gut and genital tract with concomitant loss in body weight. By 6 dpi, the infected 142 
K18-hACE2 mice lost 20% of their initial body weight, became moribund and succumbed to the 143 
infection (Figure 1D, E). In contrast, as expected, B6 mice did not experience any weight loss 144 
and survived the virus challenge. 145 
To visualize the extent of viral spread with enhanced sensitivity and resolution, we imaged 146 
individual organs after necropsy (Figure 1B, F). nLuc signal was absent in B6 mice while most 147 
organs analyzed from K18-hACE2 mice showed nLuc activity with maximum signal detected in 148 
the brain followed by the lung and nasal cavity (Figure 1F). These observations mirrored viral 149 
loads [Focus Forming Units (FFUs) and nLuc activity] in the brain, lung and nasal cavity (Figure 150 
1G, H). Real-time PCR analyses to detect N gene mRNA as well as histological analyses of 151 
organs confirmed widespread infection (Figure S1A, B). 152 
Reporter-expressing viruses often purge foreign genes, particularly in vivo, due to fitness 153 
and immune pressure (Falzarano et al., 2014; Ventura et al., 2019). To estimate the stability of 154 
nLuc reporter, we compared the copy numbers of SARS-CoV-2 nucleocapsid (N) to nLuc in the 155 
viral RNA by real-time PCR analyses of input virions and virions isolated from sera of mice at 6 156 
dpi. The ratio of copy numbers between the two samples sets did not change significantly (Figure 157 
1I) indicating that the reporter was stable throughout the experimental timeline. Thus, nLuc activity 158 
was an excellent surrogate to follow virus replication in vivo. 159 
SARS-CoV-2 infection triggers an imbalanced immune response and a cytokine storm 160 
that contributes significantly to pathogenesis (Del Valle et al., 2020). We compared the mRNA 161 
levels of inflammatory cytokines IL6, CCL2, CXCL10 and IFNγ in the lungs and brains of mice 162 
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after necropsy at 6 dpi. Indeed, most cytokines mRNAs were significantly upregulated in both 163 
organs of infected K18-hACE2 mice compared to B6 (Figure 1J, K). Overall, cytokine mRNAs 164 
were higher in the brain compared to lungs with CXCL10 mRNA copy numbers reaching ~1000 165 
fold higher in K18-hACE2 than in B6 mice corroborating extensive infection (Figure 1J, K). 166 
We next used BLI to illuminate areas of infected regions within lungs, brain, and testis for 167 
directed histology and electron tomographic studies (Figure 2). Higher resolution imaging 168 
revealed that SARS-CoV-2 virions were associated to large extent with capillary endothelial cell 169 
and/or alveolar type-1 cells in the lungs (Figure 2A-D; Video S2). In the brain, neuronal cells 170 
(MAP2+GFAP-CD68-CD11b-) were positive for SARS-CoV-2 N and EM tomography revealed an 171 
array of SARS-CoV-2 virions associated within the dendrites (Figure 2E-J, Figure S1C, Video 172 
S3). In the testis, Sertoli cells stained positively for N (Figure 2K-N, Video S4). EM tomography 173 
also showed a large population of virions within pleomorphic membrane-bound compartments of 174 
Sertoli cells.  175 
 176 
Highly Potent SARS-CoV-2 NAbs CV3-1 and CV3-25 from a Convalescent Donor   177 
We recently reported and characterized plasma from a COVID-19 convalescent subject 178 
(S006) with potent neutralizing activity and high levels of SARS-CoV-1 cross-reactive Abs (Lu et 179 
al., 2020). We probed the B cell receptor (BCR) repertoire from this donor to isolate broad and 180 
potent NAbs. Using a recombinant SARS-CoV-2 S ectodomain (S2P) as a bait to identify antigen-181 
specific B cells, we collected and screened a library of S-targeted BCR clones and identified two 182 
most potent NAb candidates: CV3-1 and CV3-25. We first characterized their epitope specificity 183 
using ELISA, cell-surface staining, virus capture assay and surface plasmon resonance (SPR) 184 
(Ding et al., 2020; Prevost et al., 2020). Both NAbs recognized SARS-CoV-2 S efficiently with a 185 
low-nanomolar affinity, as a stabilized ectodomain (S-6P) or when displayed on cells and virions 186 
(Figure 3A-E). While CV3-1 bound the SARS-CoV-2 RBD, CV3-25 targeted the S2 subunit 187 
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(Figure 3A, D-E) and cross-reacted with SARS-CoV-1 S on cells or virions, but not with S from 188 
other human Coronaviruses (Figure 3B-C). In agreement with the previous smFRET data for 189 
S006 plasma, CV3-1 stabilized S in the RBD-up (∼0.1 FRET) conformation (Figure 3F-H), as 190 
seen with hACE2 and most RBD-directed NAbs (Lu et al., 2020). Interestingly, CV3-25-bound S 191 
showed a partial shift towards downstream conformations (∼0.1 and ∼0.3 FRET), suggesting a 192 
distinct inhibitory mechanism from CV3-1 (Figure 3F-H).  193 
We next measured the ability of CV3-1 and CV3-25 to neutralize and mediate Fc-194 
dependent antibody functions. While both NAbs blocked infection by SARS-CoV-195 
2 pseudovirus or live virus and interfered with S-driven cell-to-cell fusion, CV3-1 was ~10 times 196 
more potent than CV3-25 (Figure 3I-L). To evaluate Fc-mediated effector functions of the NAbs, 197 
we used assays that quantify the ADCC and ADCP activities against S-expressing cells. CV3-1 198 
and CV3-25 efficiently bound and eliminated S-expressing cells by stimulating cytotoxic and 199 
phagocytic responses in immune effector cells (Figure 3L-N). Overall, both NAbs displayed 200 
significant neutralization and Fc-dependent antibody functions, although CV3-1 was found to be 201 
more effective for most of the assessed functions. The combination of the two NAbs (1:1 ratio) 202 
was found to be phenotypically similar to the responses seen with CV3-1 alone (Figure 3I-N). 203 
 204 
Prophylactic Treatment with NAbs Protects K18-hACE2 Mice from SARS-CoV-2 Infection  205 
We first monitored the biodistribution of Alexa Fluor (AF) conjugated CV3-1 and CV3-25 in various 206 
tissues 24 h after i.p. delivery in mice by fluorescence imaging, histology and ELISA. All three 207 
approaches revealed widespread distribution of the NAbs to multiple organs and target tissues 208 
including the nasal cavity, lung and the brain (Figure S2, S3A-D). Next, we tested a prophylactic 209 
regimen where each NAb was delivered i.p. alone (12.5 mg/kg body weight) or in 1:1 combination 210 
(6.25 mg each NAb/kg body weight) 24 h before i.n. challenge with SARS-CoV-2 nLuc (Figure 211 
4A). Temporal monitoring by whole-body BLI revealed that all three prophylactic regimens 212 
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprintthis version posted March 22, 2021. ; https://doi.org/10.1101/2021.03.22.436337doi: bioRxiv preprint 
10 
 
substantially reduced SARS-CoV-2 infection in the lungs and subsequent spread (Figure 4B-D). 213 
Remarkably, pretreatment with CV3-1 alone or in combination with CV3-25 (cocktail 1:1) 214 
produced near complete protection from SARS-CoV-2 infection with no signals detected in 215 
multiple organs after non-invasive imaging or after terminal necropsy at 22 dpi (Figure 4B-D, G, 216 
H). Moreover, all test cohorts survived with no discernible weight loss, nLuc activity or viral loads 217 
in all organs tested signifying complete control of virus infection (Figure 4E-I). Lung and 218 
subsequent neuroinvasion did occur, albeit at reduced intensity, in CV3-25-pretreated animals 219 
which was corroborated by imaging of individual organs after necropsy (Figure 4B, G, H). CV3-220 
25 delayed mortality by ~2 days in 4 out of the 6 animals and viral loads in the nasal cavity, lungs, 221 
and brain at the time of necropsy (8 dpi) were similar to that in the control cohorts treated with 222 
isotype-matched antibodies at 6 dpi (Figure 4F, I).  223 
CV3-1 or NAb cocktail pre-treatment also prevented the inflammatory cytokine induction 224 
seen in control and CV3-25 pre-treated cohorts (Figure 4J, K). In contrast, heightened levels of 225 
cytokine mRNA were detected in mice that had succumbed to infection and the control cohort 226 
(Figure 4J, K). Mice that survived in the CV3-25 pretreated cohorts, regained body weight and at 227 
22 dpi, had no detectable virus in organs and exhibited base-line inflammatory cytokine induction 228 
(Figure 4E-K). Overall, our data indicated that CV3-1 alone, or in combination with CV3-25, 229 
inhibited establishment of virus infection and fully protected K18-hACE2 mice. Histology of brain 230 
tissue revealed that NAbs CV3-1 and CV3-25 persisted even at 6 dpi (Figure S3E). Consistent 231 
with virus infection in the brain, CV3-25 localized heavily to the surface of infected neurons at 6 232 
dpi, in addition to endothelial cells, which was predominantly observed before infection. In 233 
contrast, CV3-1 localization remained unaltered due to the absence of viral neuroinvasion in this 234 
cohort (Figure S3E). In addition, in vivo dose response studies revealed that as little as 0.75 mg 235 
CV3-1/kg body weight protected 50% of the treated cohort from lethal SARS-CoV-2 infection 236 
(Figure S4). These data indicated that CV3-1 is highly potent at halting SARS-CoV-2 infection 237 
and contributed to protection observed in the cohort treated with the cocktail. 238 
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CV3-1 Therapy Recues Mice from Lethal SARS-CoV-2 Infection 239 
CV3-1 NAb alone completely protected K18-hACE2 mice against SARS-CoV-2-induced mortality. 240 
We therefore explored if CV3-1 could also cure infected mice. Mice infected with SARS-CoV-2-241 
nLuc were administered CV3-1 at 1, 3, and 4 dpi after confirming SARS-CoV-2 infection was 242 
established in the lungs of all mice (Figure 5A). Temporal imaging and quantification of nLuc 243 
signal revealed that CV3-1, when administered at 1 and 3 dpi, controlled virus spread and 244 
successfully prevented neuroinvasion (Figure 5B-D, G, H). This was corroborated by no weight 245 
loss and/or recuperation of body weight, undetectable viral loads as well as near-baseline levels 246 
of inflammatory cytokines in tissues (Figure 5E-K). CV3-1 therapy at 4 dpi, however, could neither 247 
control virus spread nor neuroinvasion resulting in death of 75% of the mice in this cohort (Figure 248 
5B-F) with loss in body weight, high levels of inflammatory cytokines and tissue viral loads, similar 249 
to that in the control cohort (Figure 5E-K). Thus, the therapeutic window of maximal efficacy for 250 
CV3-1 treatment extends for up to 3 days from the initiation of SARS-CoV-2 infection to 251 
successfully prevent lethality. 252 
 253 
CV3-1 and CV3-25 Require Antibody Effector Functions For in vivo efficacy 254 
Highly potent antibodies can effectively neutralize free viruses and may also mediate Fc-255 
recruitment of immune cells to eliminate infected cells. We therefore explored a role for Fc-256 
mediated effector functions in protection in vivo. We generated Leucine to Alanine (L234A/L235A, 257 
LALA) mutant versions of both NAbs to impair interaction with Fc receptors (Saunders, 2019). 258 
Our in vitro assays confirmed that, while ADCC and ADCP activities were compromised, LALA 259 
mutations had no impact on S binding and neutralizing capacities of both NAbs (Figure S5). 260 
Biodistribution analyses of AF647-conjugated CV3-1 and CV3-25 LALA NAbs, 24h after i.p. 261 
administration indicated penetration into most tissues (Figure S5).  262 
 We next tested the impact of LALA mutations on the prophylactic efficacy of CV3-1 and 263 
CV3-25 (Figure S6A). Longitudinal non-invasive BLI and terminal imaging analyses after 264 
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necropsy, body weight changes, survival and viral load estimations revealed that LALA mutations 265 
had indeed compromised the protective efficacy of both antibodies (Figure S6A-I). SARS-CoV-2 266 
replicated better, invaded the brain and induce body weight loss in cohorts treated with LALA 267 
NAbs compared to the corresponding wild-type NAbs (Figure S6D-E). Histology at 6 dpi revealed 268 
that both LALA NAbs had penetrated the brain tissue during the course of infection and bound 269 
the surface of infected neurons (Figure S5G, H). While CV3-1-treated animals had no detectable 270 
viral loads at 6 dpi, CV3-1 LALA pretreated mice had higher tissue viral loads indicating 271 
compromised protective efficacy (Figure S6I). Similarly, while tissue viral loads in CV3-25 treated 272 
mice were reduced by a log, those in CV3-25 LALA treated mice were comparable to that in 273 
control cohorts. Moreover, the delayed mortality and 25% protective efficacy offered by CV3-25 274 
was abrogated and the ability of CV3-1 to provide 100% protection from SARS-CoV-2-induced 275 
mortality was reduced to 62.5% with the corresponding LALA mutants (Figure S6F). Additionally, 276 
there was an overall increase in the signature inflammatory cytokine profile in mice pre-treated 277 
with LALA NAbs (Figure S6J, K).  278 
The requirement for Fc effector function during CV3-1 prophylaxis was surprising as we 279 
did not detected infection in CV3-1 treated mice both by non-invasive and post-necropsy tissue 280 
imaging at 6 dpi (Figure 4). However, examination of tissues at 3 dpi did reveal weak nLuc signals 281 
in the nasal cavity and lungs despite absence of signal by non-invasive imaging (Figure S5J-M). 282 
PCR analyses also confirmed the presence SARS-CoV-2 N RNA in these tissues at 3 dpi (Figure 283 
S5N). The data indicated that some of the incoming virions did not encounter CV3-1 and managed 284 
to establish infection during prophylaxis and hence Fc effector functions were required to 285 
eliminate them. 286 
Our data thus implied that immune cell components would be critical during CV3-1 therapy 287 
(Figure 6A). Indeed, while CV3-1 treatment at 3 dpi controlled infection, cohorts treated with CV3-288 
1 LALA displayed rapidly spreading lung infection and fully succumbed by 6 dpi after an 289 
accelerated loss in body weight (Figure 6B-F). High viral loads and cytokine levels in nose, lung, 290 
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and brain also reflected the failure of the LALA NAbs to treat pre-established viral infection (Figure 291 
6G). Notably, while the lung viral loads in CV3-1 LALA NAb-treated cohort were similar to that in 292 
the control, inflammatory cytokine mRNA levels in lungs, CXCL10 in particular, were significantly 293 
higher suggesting a crucial requirement for Fc-engagement in curbing a cytokine-storm like 294 
phenotype (Figure 6H-I). 295 
 296 
Monocytes and NK cells Contribute to Antibody-mediated Effector Functions In Vivo 297 
To identify the immune cell types engaged by NAbs, we initiated NK cell depletion (α-NK1.1) prior 298 
to CV3-1 prophylaxis. Flow cytometric analyses confirmed NK cell depletion in α-NK1.1 treated 299 
cohorts. (Figure S7J, K). Our BLI-guided analyses showed appearance of weak nLuc signals in 300 
lungs of infected mice prophylactically treated with CV3-1 as well as αNK1.1 mAbs compared to 301 
those in the control cohort treated with CV3-1 and with an isotype control (Figure S7A-D). In 302 
addition, two of the mice that underwent NK cell depletion in the CV3-1 pretreated group 303 
experienced a temporary but significant decrease in body weight before recovering (Figure S7E). 304 
Nevertheless, all the mice receiving CV3-1 prophylaxis survived despite NK cell depletion (Figure 305 
S7F). We did observe a marginal increase in viral loads in target organs upon NK depletion in 306 
mice under CV3-1 prophylaxis (Figure S7G). In addition, the ability of CV3-1 to suppress 307 
inflammatory cytokines was significantly compromised upon NK cell-depletion (Figure S7H, I-K). 308 
Thus, while NK cells do contribute to in vivo efficacy of CV3-1, their requirement was not 309 
significant enough to compromise protection offered by CV3-1 prophylaxis.  310 
To investigate NK cell-requirement during CV3-1 therapy, we depleted them in SARS-311 
CoV-2-nLuc infected mice where CV3-1 treatment was initiated at 3 dpi (Figure 7A). Our BLI-312 
centric multiparametric analyses revealed that NK cell depletion partially compromised the 313 
efficacy of CV3-1 therapy with 25% of the mice succumbing to SARS-CoV-2 infection compared 314 
to CV3-1-treated controls where all the mice survived (Figure 7B-F). We next investigated if 315 
Ly6G+ neutrophils and Ly6Chi CD11b+ classical monocytes accounted for additional Fc effector 316 
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activities by using the anti-Ly6G and anti-CCR2 depleting mAbs in mice under CV3-1 therapy 317 
(Figure 7A, B, S7L-O) (Mack et al., 2001). Neutrophil or monocyte depletion under CV3-1 therapy 318 
led to 75% and 80% of the mice failed to control SARS-CoV-2 spread and loss in body weight 319 
resulting in death although neuroinvasion was overall weaker than isotype control cohorts (Figure 320 
7B-E, G). Neutrophil or monocyte depletion in the setting of CV3-1 therapy led to increased viral 321 
burden and enhanced expression of CCL2, CXCL10, and Il6 mRNA in target tissues compared 322 
to the cohort under CV3-1 therapy (Figure 7H-J). These data indicated that neutrophils, 323 
monocytes and NK cells contributed to the antibody-dependent cure of mice from lethal SARS-324 
CoV-2 infection and are critical for the success of SARS-CoV-2 NAb-directed therapies. 325 
Together, our data demonstrate the utility of a BLI-guided platform for temporo-spatial 326 
visualization of SARS-CoV-2 replication, pathogenesis and the mechanisms contributing to an 327 
effective outcome with NAb-based interventions in vivo in the K18-ACE2 mouse model. 328 
 329 
Discussion 330 
NAb therapies are being explored to augment current vaccination strategies against 331 
SARS-CoV-2 to expand the protection afforded towards newly arising virus variants. However, 332 
prior evidence of antibody-dependent enhancement of pathology caused by respiratory viruses 333 
like RSV and SARS-CoV-1 warrants careful investigation of antibody effects in vivo before clinical 334 
implementation (Iwasaki and Yang, 2020; Klasse and Moore, 2020). We have established a 335 
whole-body imaging approach to follow the dynamics and pathogenesis of SARS-CoV-2 infection 336 
in mice to facilitate preclinical studies for identifying effective therapeutic measures against 337 
COVID-19. Temporal tracking of K18-hACE2 mice revealed that SARS-CoV-2 first replicates in 338 
the nasal cavity, reaches the lungs at 1 dpi where the infection expands till 3 dpi before spreading 339 
systemically to other organs including the brain by 4 dpi. BLI also helped illuminate how the highly 340 
potent human NAbs CV3-1 (targets Spike RBD) and CV3-25 (binds S2 domain) differed in their 341 
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ability to protect or treat SARS-Cov-2 infection in the highly susceptible K18-hACE2 mouse 342 
model. Imaging analyses revealed widespread NAb distribution within the animals, including in 343 
the nasal cavity and lung where the virus initially establishes infection, and persistence for at least 344 
a week after administration, features that were critical for efficacy in this acute model for SARS-345 
Cov-2. BLI also revealed a therapeutic window of 3 dpi for CV3-1 NAb to successfully halt 346 
progression of established infection in the lungs and distal tissues. Given that the previously 347 
reported SARS-CoV-2 NAbs have a therapeutic window of 1 dpi (Alsoussi et al., 2020; Hassan et 348 
al., 2020; Schafer et al., 2021; Winkler et al., 2021). CV3-1 displays one of the most potent in vivo 349 
efficacy profile with a widened therapeutic window till 3 dpi. Most protective human NAbs for 350 
SARS-Cov-2 tested in animal models and also in humans, target RBD (Baum et al., 2020; Chen 351 
et al., 2021; Rogers et al., 2020; Schafer et al., 2021; Tortorici et al., 2020; Weinreich et al., 2021), 352 
some NTD targeting NAbs also display potent antiviral activity in vivo (Li et al., 2021; Noy-Porat 353 
et al., 2021; Voss et al., 2020). We show that the S2-directed CV3-25 NAb also conferred 354 
protection, albeit not as potent as CV3-1. This of significance as newly emerging variants display 355 
fewer mutations in the S2 subunit compared to the S1 subunit. Indeed, CV3-25 has been found 356 
to efficiently neutralize the B.1.351 variant, while neutralization capacities of anti-NTD and anti-357 
RBD NAbs were greatly diminished (Stamatatos et al., 2021). 358 
 Our data also establishes that neutralizing capacity alone is not enough to garner clinical 359 
protection by NAbs. LALA variants of CV3-1 revealed a crucial role for Fc-mediated interactions 360 
in augmenting in vivo protection for prophylaxis as well as therapy. The requirement for Fc effector 361 
functions during CV3-1 prophylaxis, needed for eliminate infected cells originating from virions 362 
that eluded neutralization, is noteworthy and contrasting to a recent report where they were 363 
required only during NAb therapy (Winkler et al., 2021). Introducing LALA mutation in CV3-1 364 
completely compromised its ability to therapeutically cure and was in agreement with previous 365 
observations (Winkler et al., 2021). Surprisingly, we noticed a more severe loss in body weight in 366 
mice that were therapeutically administered CV3-1 LALA variants and significantly higher 367 
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inflammatory responses (CCL2, CXCL10, IFNγ) in lungs than isotype-treated control animals. 368 
These data suggest that the Fc region plays an additional protective role by limiting 369 
immunopathology through dampening of inflammatory responses. A previously reported NAb 370 
engaged only monocytes for in vivo activity (Winkler et al., 2021). However, our studies revealed 371 
that CV3-1 engaged Fc-interacting neutrophils, monocytes and NK cells for its in vivo efficacy. 372 
Thus, in addition to its potent neutralizing activity, a superior engagement of innate immune 373 
components contributed to the high in vivo potency of CV3-1  374 
Experiments using low doses of NAbs indicated that CV3-1 did not enhance infection at 375 
concentrations that protected only 50% of animals in the group. Thus, our data add to the growing 376 
body of evidence that suggest the absence of an antibody-dependent enhancement (ADE) 377 
mechanism with a protective rather than a pathogenic role for Fc effects during SARS-CoV-2 378 
infection (Schafer et al., 2021; Winkler et al., 2021). However, while mouse FcγRs bind human 379 
antibodies with similar affinities as mouse antibodies, their expression pattern on various mouse 380 
immune cells differs from those in humans. Therefore, additional investigations in other models 381 
are required to confirm definitive absence of ADE during human SARS-CoV-2 infection (Gorman 382 
et al., 2021). Moreover, elucidation of the major FcγR(s) (FcγRI, FcγRIII and/or FcγRIV) engaged 383 
by NAbs will help design ultrapotent SARS-CoV-2 Nab therapies (Smith et al., 2012).  384 
In summary, our study demonstrates the utility of the BLI-guided approach to study SARS-385 
CoV-2 pathogenesis and identify effective antiviral therapies for rapid translation to clinical use in 386 
humans. 387 
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Figure Legends 421 
Figure 1. Visualization of SARS-CoV-2 Replication Dynamics in hACE2 Transgenic Mice 422 
(A) Experimental strategy utilizing SARS-CoV-2 carrying nLuc reporter in ORF7 for non-invasive 423 
BLI of virus spread following intranasal (i.n.) challenge of B6 or K18-hACE2 mice. 424 
(B) Representative images from temporal BLI of SARS-CoV-2-nLuc-infected mice in ventral (v) 425 
and dorsal (d) positions at the indicated dpi and after necropsy at 6 dpi. 426 
(C) Temporal quantification of nLuc signal as flux (photons/sec) acquired non-invasively in the 427 
indicated tissues of each animal. The color bar above the x-axis (yellow to orange) represents 428 
computed signal intensities in K18-hACE2 mice that are significantly above those in B6 mice. 429 
(D) Temporal changes in mouse body weight at the indicated dpi with initial body weight set to 430 
100%.  431 
(E) Kaplan-Meier survival curves of mice for experiment as in A statistically compared by log-rank 432 
(Mantel-Cox) test. 433 
(F) Ex vivo imaging of indicated organs and quantification of nLuc signal as flux(photons/sec) at 434 
indicated dpi after necropsy 435 
(G, H) Viral loads (FFUs/g or nLuc activity/g) from indicated tissue using Vero E6 cells as targets. 436 
Undetectable virus amounts were set to 1. 437 
(I) Ratio of Ct values for SARS-CoV-2 nucleocapsid (N) and nLuc estimated by RT-PCR using 438 
RNA extracted from input virions (inoculum) and virions from sera of mice at 6 dpi. 439 
(J, K) Cytokine mRNA levels in lung and brain tissues at 6 dpi after normalization to Gapdh in the 440 
same sample and that in uninfected mice. 441 
Each curve in (C) and (D) and each data point in (F), (I), (J), and (K) represents an individual 442 
mouse. Scale bars in (B and (F) denote radiance (photons/sec/cm2/steradian). p values obtained 443 
by non-parametric Mann-Whitney test for pairwise comparison. ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 444 
0.001; ∗∗∗∗, p < 0.0001; ns, not significant; Mean values ± SD are depicted. 445 
 446 
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Figure 2. EM localization of SARS-CoV-2 Virions in Lung, Brain and Testis of Infected K18-447 
hACE2 Mice. (A) 2D overview of a lung region featuring red blood cells (rbc) within a pulmonary 448 
capillary, an alveolar Type 2 cell (AT2).  449 
(B) Slice from a 3D tomogram of square region in A showing membrane-enclosed cytoplasmic 450 
compartments (arrowheads) containing presumptive SARS-CoV-2 virions in capillary endothelial 451 
cells.  452 
(C) Presumptive virions from tomogram in B displayed at equatorial views. Presumptive virions 453 
were identified as described in the Methods and are directly comparable to those in SARS-CoV-454 
2 infected Vero-E6 cells (panels O-Q).  455 
(D) ImmunoEM tomography of presumptive SARS-CoV-2 virions from infected lung tissue, 456 
labeled with antiserum against Spike protein and gold (10 nm) conjugated 2° antibodies. Gold 457 
particles localized to the outer peripheries of the virions indicate specific labeling of SARS-CoV-458 
2 Spikes.  459 
(E) Tomographic of SARS-CoV-2 infected brain tissue. Presumptive SARS-CoV-2 virions (red 460 
arrowheads) are present within a neuron (pale green). A dendritic synaptic terminal to the left of 461 
the virus-containing neuron shows that presumptive SARS-CoV-2 virions are easily distinguished 462 
from typical synaptic neurotransmitter vesicles.  463 
(F) 2D overview of brain tissue illustrating the complex spatial relationship among neurons and 464 
other brain cell types.  Presumptive SARS-CoV-2 virions are present in two compartments (black 465 
squares) within a single neuron.  466 
(G, H) Tomographic slices of black squares in F. Presumptive SARS-CoV-2 virions (red 467 
arrowheads) appear to be aligned within compartments that border the edges of a neural 468 
projection.  469 
(I) Presumptive SARS-CoV-2 virions from tomograms in G and H. 470 
(J) ImmunoEM tomography as in D of presumptive SARS-CoV-2 virions from infected brain tissue.  471 
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(K) (Upper) BLI of testis from a SARS-CoV-2 infected mouse to identify infected regions for IF 472 
and EM analyses. (Lower) IF image of an infected testis region stained with antibodies to SARS-473 
CoV-2 Nucleocapsid (red)  474 
(L) 2D overview of testis corresponding to region of high intensity (red) in the upper panel of K, 475 
showing Sertoli cells surrounded by developing sperm (left) and one primary spermatocyte (1°S, 476 
upper right). Presumptive SARS-CoV-2 virions are localized to membrane-bound compartments 477 
in Sertoli cells (black squares).  478 
(M, N) Slices from two 3D tomograms of squares in L. Presumptive SARS-CoV-2 virions 479 
(arrowheads) are present within membrane-enclosed cytoplasmic compartments. These 480 
compartments contain additional structures amongst the discernable SARS-CoV-2 virions 481 
(insets). 482 
(O) EM localization of virions in SARS-CoV-2 infected Vero-E6 cells, processed for EM as above 483 
tissue samples. Virions were characterized (see Methods) and compared to presumptive virions 484 
in the tissue samples to confidently verify their identities. 2D overview of infected Vero-E6 cell in 485 
a 150 nm section. 486 
(P) Tomogram of rectangle in O showing >100 presumptive SARS-CoV-2 virions contained within 487 
cytoplasmic exit compartments.  488 
(Q) Virions from the tomogram in P showing common features of dense RNC puncta, discernable 489 
surface spikes, vary in size (~60-120 nm) and shape. Virions are directly comparable to those 490 
shown for the tissue samples in C and I. 491 
 492 
Figure 3. In vitro Characterization of CV3-1 and CV3-25 NAbs. (A) NAb binding to SARS-CoV-493 
2 Spike ectodomain (S-6P) or RBD estimated by ELISA. Relative light unit (RLU) were normalized 494 
to the cross-reactive SARS-CoV-1 NAb CR3022. NAb binding to SARS-CoV-2 S2 N-His protein 495 
on cell-surface of transfected 293T cells analyzed by flow cytometry. Median fluorescence 496 
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intensities (MFIs) for anti-Spike NAbs were normalized to the signal obtained with an anti-His tag 497 
mAb.  498 
(B) Flow cytometric detection of S-expressing 293T cells from the different human CoVs: SARS-499 
CoV-2, SARS-CoV-1, OC43, HKU1, MERS-CoV, NL63 and 229E.  MFI from 293T cells 500 
transfected with empty vector were used for normalization.  501 
(C) Pseudoviruses bearing SARS-CoV-2 or SARS-CoV-1 S were tested for capture by anti-502 
Spike NAbs. The cross-reactive CR3022 mAb was used for normalization.  503 
(D-E) NAb binding affinity and kinetics to SARS-CoV-2 S using Surface Plasmon Resonance 504 
(SPR). SARS-CoV-2 S-6P or S2 ectodomain was immobilized as the ligand on the chip and CV3-505 
1 or CV3-25 Fab was used as analytes at concentrations in a range from 1.56 to 100 nM for both 506 
Fabs to S-6P and 3.125nM to 200nM for CV3-25 to S2 (2-fold serial dilution, see Methods for 507 
details). Alternatively, CV3-1 IgG was immobilized on the chip and SARS-CoV-2 RBD was used 508 
as the analyte with concentrations ranging from 1.56 to 50 nM (2-fold serial dilution). Kinetic 509 
constants were determined using a 1:1 Langmuir model in BIA evaluation software (experimental 510 
readings shown in blue and fitted curves shown in black). 511 
(F-H) FRET histograms of ligand-free S on S-MEN coronavirus-like particles (VLPs) or in 512 
presence of 50 µg/mL of CV3-1 (G) or CV3-25 (H). VLPs were incubated for 1 h at 37oC before 513 
smFRET imaging. Nm is the number of individual FRET traces compiled into a conformation-514 
population FRET histogram (gray lines) and fitted into a 4-state Gaussian distribution (solid black) 515 
centered at 0.1-FRET (dashed cyan), 0.3-FRET (dashed red), 0.5-FRET (dashed green), and 0.8-516 
FRET (dashed magenta).  517 
(I) Neutralizing activity of CV3-1 and CV3-25 alone or in combination (1:1 ratio) on SARS-CoV-2 518 
S bearing pseudoviruses using 293T-ACE2 cells.  519 
(J) Microneutralization activity of anti-Spike NAbs on live SARS-CoV-2 virus using Vero E6 cells.  520 
(K) Inhibition of cell-to-cell fusion between 293T cells expressing HIV-1 Tat and SARS-CoV-2 S 521 
and TZM-bl-ACE2 cells by NAbs.  522 
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprintthis version posted March 22, 2021. ; https://doi.org/10.1101/2021.03.22.436337doi: bioRxiv preprint 
23 
 
Half maximal inhibitory antibody concentration (IC50) values in I-K were determined by normalized 523 
non-linear regression analyses.  524 
(L) MFI of CEM.NKr cells expressing SARS-CoV-2 Spike (CEM.NKr-Spike) stained with indicated 525 
amounts of NAbs and normalized to parental CEM.NKr. 526 
(M) % ADCC in the presence of titrated amounts of NAbs using 1:1 ratio of parental CEM.NKr 527 
cells and CEM.NKr-Spike cells as targets when PBMCs from uninfected donors were used as 528 
effector cells 529 
(N) % ADCP in the presence of titrated amounts of NAbs using CEM.NKr-Spike cells as targets 530 
and THP-1 cells as phagocytic cells.  531 
 532 
Figure 4. Prophylactic Treatment with CV3-1 Protects Mice from Lethal SARS-CoV-2 533 
Infection. (A) Experimental design for testing in vivo efficacy of NAbs CV3-1 and CV3-25 534 
administered alone (12.5 mg/kg body weight) or as a 1:1 cocktail (6.25 mg/kg body weight each) 535 
1 day prior to challenging K18-hACE2 mice (i.n.) with SARS-CoV-2-nLuc followed by non-invasive 536 
BLI every 2 days. Human IgG1-treated (12.5 mg Ig/kg) mice were use as the isotype control (Iso) 537 
(B) Representative images from BLI of SARS-CoV-2-nLuc-infected mice in ventral (v) and dorsal 538 
(d) positions at the indicated dpi and after necropsy at indicated days for experiment as in A. 539 
(C-D) Temporal quantification of nLuc signal as flux (photons/sec) computed non-invasively in 540 
indicated areas of each animal. 541 
(E) Temporal changes in mouse body weight at the indicated dpi with initial body weight set to 542 
100%. 543 
(F) Kaplan-Meier survival curves of mice statistically compared by log-rank (Mantel-Cox) test for 544 
experiment as in A. 545 
(G, H) Ex-vivo imaging of organs and quantification of nLuc signal as flux (photons/sec) at the 546 
indicated dpi after necropsy. 547 
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(I) Viral loads (nLuc activity/g) from indicated organs using Vero E6 cells as targets. Undetectable 548 
virus amounts were set to 1.  549 
(J, K) Cytokine mRNA levels in lung and brain tissues after necropsy normalized to Gapdh in the 550 
same sample and that in uninfected mice.  551 
Viral loads (I) and inflammatory cytokine profile (J, K) were determined after necropsy for mice 552 
that succumbed to infection and in mice surviving at 22 dpi.  553 
Scale bars in (B) and (G) denote radiance (photons/sec/cm2/steradian). Each curve in (C)-(E) and 554 
each data point in (H)-(K) represents an individual mouse. Grouped data in (C)-(K) were analyzed 555 
by 2-way ANOVA followed by Dunnett’s or Tukey’s multiple comparison tests. Statistical 556 
significance for group comparisons to isotype control are shown in black and for those to CV3-25 557 
are shown in red ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001; ∗∗∗∗, p < 0.0001; Mean values ± SD are 558 
depicted. 559 
 560 
Figure 5. CV3-1 Therapy Protects Mice from Lethal SARS-CoV-2 Infection. (A) Experimental 561 
design to test in vivo efficacy of CV3-1 administered i.p. (12.5 mg/kg body weight) at indicated 562 
times after i.n. challenge of K18-hACE2 mice with SARS-CoV-2 nLuc followed by non-invasive 563 
BLI every 2 days. Human IgG1 treated (12.5 mg/kg body weight) mice were the control cohort.  564 
(B) Representative images from temporal BLI of SARS-CoV-2-nLuc-infected mice in ventral (v) 565 
and dorsal (d) positions at the indicated dpi and after necropsy. 566 
(C-D) Temporal quantification of nLuc signal acquired non-invasively as flux (photons/sec) in 567 
indicated regions of each mice.  568 
(E) Temporal changes in mouse body weight at indicated dpi with initial body weight set to 100%. 569 
(F) Kaplan-Meier survival curves of mice statistically compared by log-rank (Mantel-Cox) test for 570 
experiment as in A. 571 
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(G, H) Ex vivo imaging of indicated organs and quantification of nLuc signal as flux(photons/sec) 572 
at indicated dpi after necropsy. 573 
(I) Viral loads estimated as nLuc activity/g of indicated organs using Vero E6 cells as targets. 574 
Non-detectable virus amounts were set to 1. 575 
(J, K) Cytokine mRNA levels in lung and brain tissues after necropsy. The data was normalized 576 
to Gapdh in the same sample and that in uninfected mice. 577 
Viral loads (I) and inflammatory cytokine profile (J, K) were determined after necropsy at times 578 
indicated in G. Each curve in (C)-(E) and each data point in (H)-(K) represents an individual 579 
mouse. CV3-1 treatment times are indicated in (C)-(E). Grouped data in (C)-(K) were analyzed 580 
by 2-way ANOVA followed by Dunnett’s or Tukey’s multiple comparison tests. Statistical 581 
significance for group comparisons to isotype control are shown in black and for those under CV3-582 
1 therapies to 4 dpi-treated cohorts are shown in red. ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001; 583 
∗∗∗∗, p < 0.0001; Mean values ± SD are depicted. 584 
 585 
Figure 6. Fc-mediated Antibody Effector Functions Contribute to the In Vivo Efficacy of 586 
CV3-1 (A) Experimental design to test therapeutic efficacy of NAb CV3-1 and its corresponding 587 
Leucine to Alanine (LALA) mutant administered ip (12.5 mg/kg body weight) 3 dpi to K18-hACE2 588 
mice challenged with SARS-CoV-2 nLuc followed by non-invasive BLI every 2 days. Human IgG1-589 
treated (12.5 mg/kg body weight) mice were used as the control cohort.  590 
(B) Representative images from temporal BLI of SARS-CoV-2-nLuc-infected mice in ventral (v) 591 
and dorsal (d) positions at the indicated dpi and after necropsy. Scale bars denote radiance 592 
(photons/sec/cm2/steradian). 593 
(C-D) Temporal quantification of nLuc signal acquired non-invasively as flux (photons/sec) in 594 
indicated regions. 595 
(E) Temporal changes in mouse body weight at indicated dpi with initial body weight set to 100%.  596 
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(F) Kaplan-Meier survival curves of mice statistically compared by log-rank (Mantel-Cox) test. for 597 
experiment as in A.  598 
(G) Viral loads (nLuc activity/g) in indicated organs using Vero E6 cells as targets. Undetectable 599 
virus amounts were set to 1. 600 
(H, I) Cytokine mRNA levels in lung and brain tissues after necropsy. The values were normalized 601 
to Gapdh in the same sample and that in uninfected mice. 602 
Viral loads (G) and inflammatory cytokine profile (H, I) was determined after necropsy at times 603 
indicated in B. Each curve in (C)-(E) and each data point in (G)-(I) represents an individual mouse. 604 
CV3-1 treatment times are indicated in (C)-(E). Grouped data in (C)-(I) were analyzed by 2-way 605 
ANOVA followed by Dunnett’s or Tukey’s multiple comparison tests. Statistical significance for 606 
group comparisons to isotype control are shown in black and between CV3-1 and CV3-1 LALA 607 
treated cohorts are shown in red. ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001; ∗∗∗∗, p < 0.0001; Mean 608 
values ± SD are depicted. 609 
  610 
Figure 7. Monocytes, Neutrophils and Natural Killer Cells Contribute to Antibody Effector 611 
Functions In Vivo. (A) Experimental design to test the contribution of NK cells, neutrophils 612 
(CD11b+Ly6G+) and monocytes (CCR2+Ly6hi CD11b+) in K18-hACE2 mice therapeutically treated 613 
with CV3-1 NAb (i.p.,12.5 mg/kg body weight) at 3 dpi after challenge with SARS-CoV-2-nLuc. 614 
αNK1.1 mAb (i.p., 20 mg/kg body weight), αLy6G mAb (i.p., 20 mg/kg body weight) and αCCR2 615 
mAb (i.p., 2.5 mg/kg body weight) were used to deplete NK cells, neutrophils and monocytes 616 
respectively every 48h starting at 1 dpi. Corresponding human (for CV3-1) and rat (for αNK1.1 617 
and αLy6G mAb or αCCR2) monoclonal antibodies served as non-specific isotype controls (Iso). 618 
The mice were followed by non-invasive BLI every 2 days from the start of infection.  619 
(B) Representative images from temporal BLI of SARS-CoV-2-nLuc-infected mice in ventral (v) 620 
and dorsal (d) positions at the indicated dpi and after necropsy. 621 
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(C-D) Temporal quantification of nLuc signal acquired non-invasively as flux (photons/sec) in 622 
indicated regions.  623 
(E) Temporal changes in mouse body weight at indicated dpi with initial body weight set to 100%.  624 
(F) Kaplan-Meier survival curves of mice statistically compared by log-rank (Mantel-Cox) test for 625 
experiment as in A. 626 
(H) Viral loads (nLuc activity/g) of indicated organs using Vero E6 cells as targets. Undetectable 627 
virus amounts were set to 1. 628 
(I, J) Cytokine mRNA levels in lung and brain tissues after necropsy and normalization to GAPDH 629 
in the same sample and that in uninfected mice. 630 
Viral loads (H) and inflammatory cytokine profile (I, J) was determined after necropsy at times 631 
indicated in B. Each curve in C-E and each data point in H-J represents an individual mouse.  632 
Grouped data in (C)-(I) were analyzed by 2-way ANOVA followed by Dunnett’s or Tukey’s multiple 633 
comparison tests. Statistical significance: group comparisons to isotype control are shown in 634 
black; group comparisons to Iso+CV3-1 within the NK and neutrophil depleted cohorts are shown 635 
in purple; group comparisons to Iso+CV3-1 within the monocyte-depleted cohorts are shown in 636 
red. ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001; ∗∗∗∗, p < 0.0001; Mean values ± SD are depicted.  637 
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprintthis version posted March 22, 2021. ; https://doi.org/10.1101/2021.03.22.436337doi: bioRxiv preprint 
28 
 
Supplementary Figure Legends: 638 
Figure S1. Widespread SAR-CoV-2 infection in K18-hACE2 mice. Related to Figure 1. (A) A 639 
plot showing real-time PCR analyses to detect SARS-CoV-2 nucleocapsid (N) gene mRNA in 640 
indicated organs of B6 and K18-hACE2 mice at 6 dpi intranasally challenged with 1 x 105 FFU of 641 
SARS-CoV-2-nLuc. The data were normalized to N RNA seen in uninfected mice and GAPDH 642 
mRNA levels. p values obtained by non-parametric Mann-Whitney test for pairwise comparison. 643 
∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001; ∗∗∗∗, p < 0.0001; ns, not significant; Mean values ± SD 644 
are depicted. 645 
(B) Images of cryosections from indicated tissues of SARS-CoV-2-nLuc infected K18-hACE2 646 
mouse harvested at 6 dpi. Actin (green), nucleocapsid (red) and hACE2 (magenta) were detected 647 
using phalloidin and respective antibodies. Notably, hACE2 appeared as puncta on the surface 648 
of infected neurons and lung tissue compared to other organs where the signal was more uniform 649 
and stained a region of the cell surface. Scale bar: 50 µm 650 
(C) Images of cryosections from brain tissues of SARS-CoV-2-nLuc infected K18-hACE2 mouse 651 
harvested at 6 dpi to characterize infected cells. Glial cells (top panel) were identified using 652 
antibodies to markers CD68 (magenta) and CD11b (green). Neurons (lower panel) were identified 653 
using antibodies to MAP2 (green) and mature astrocytes were identified using antibodies to GFAP 654 
(magenta). SARS-CoV-2 infected cells were identified using antibodies to nucleocapsid (red). 655 
Nucleocapsid positive cells were predominantly positive for MAP2. Scale bar: 20 µm 656 
 657 
Figure S2. Widespread biodistribution of CV3-25 and CV3-1 NAbs in mice 24 h after 658 
intraperitoneal delivery. Related to Figure 3. (A) C57BL/6J mice were either mock treated 659 
(PBS) or intraperitoneally administered 12.5 mg/kg body weight of CV3-25 monoclonal antibody 660 
conjugated to Alexa Fluor 594 (CV3-25 AF594). 24 h later, indicated tissues were imaged using 661 
the fluorescence module in IVIS spectrum to detect AF594. The plot shows the quantified 662 
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radiance detected in indicated tissues after normalization with corresponding organs from control 663 
mouse.  664 
(B) Images of cryosections from indicated tissues from CV3-25 AF594-treated mouse as in A. 665 
Actin and CV3-25 were detected using phalloidin-AF488 and AF647 conjugated anti-human IgG 666 
respectively. Scale bar: 20 µm 667 
(C) C57BL/6J mice were either mock treated (PBS) or intraperitoneally administered 12.5 668 
mg/kg of CV3-1 monoclonal antibody conjugated to Alexa Fluor 647 (CV3-25 AF647). 24 h later, 669 
indicated tissues were imaged using the fluorescence module in IVIS spectrum to detect AF647. 670 
The plot shows the quantified radiance detected in indicated tissues after normalization with 671 
corresponding organs from control mouse. 672 
(B) Images of cryosections from indicated tissues from CV3-1 AF647-treated mouse as in A. Actin 673 
was detected using phalloidin-Alexa Fluor 488. CV3-1 AF647 was detected in the red channel 674 
using Alexa Fluor 568 conjugated anti-human IgG. Scale bar: 20 µm 675 
 676 
Figure S3. Assessment of CV3-1 and CV3-25 NAbs biodistribution in mice using ELISA and 677 
immunohistology. Related to Figure 4. (A-D) Estimation of CV3-25 and CV3-1 NAbs 678 
biodistribution in mice using ELISA. Measurement of anti-Spike NAbs levels in organs was 679 
performed using quantitative ELISA. (A-B) Recombinant SARS-CoV-2 RBD and (C-D) S-6P 680 
proteins were used to quantify CV3-1 and CV3-25 antibody levels, respectively. Linear standard 681 
curves using known concentrations of CV3-1 or CV3-25 NAbs were established for inferring the 682 
antibody concentration in organ homogenates. Serial dilutions of homogenized mice organs were 683 
prepared in PBS and incubate on antigen-coated plates. The presence of anti-Spike NAbs was 684 
revealed using HRP-conjugated anti-human IgG secondary Abs. The signal obtained with BSA 685 
(negative control) was subtracted for each organ. Relative light unit (RLU) values were 686 
transformed into a NAb concentrations based on the standard curve and the dilution 687 
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factor. Subsequently, these concentration values were multiplied with the homogenization volume 688 
and divided by the total organ weight.  689 
(E) Persistence and redistribution of neutralizing NAbs in SARS-CoV-2 infected mice. Images of 690 
brain tissue from K18-hACE2 mice infected with SARS-CoV-2-nLuc at 6 dpi that were 691 
prophylactically treated with CV3-1 or CV3-25 (12.5 mg/kg body weight), 24 h before infection. 692 
Actin (green) was labelled using phalloidin, CV3-1 and CV3-25 (magenta) were detected using 693 
anti-hIgG conjugated to Alexa Fluor 647 and infected cells (red) were identified using antibodies 694 
to SARS-CoV-2 N. CV3-1 localizes to the endothelial walls of blood vessels and CV3-25 695 
redistributes to decorate infected neurons in addition to endothelium (seen in UI mice; Figure S2). 696 
Scale bar: 50 µm  697 
 698 
Figure S4. Efficacious dose for CV3-1 NAb during prophylaxis. Related to Figure 4. (A) A 699 
scheme showing experimental design for testing the dose of CV3-1 NAb to achieve protection for 700 
lethal SARS-CoV-2-nLuc infection. Indicated concentration of CV3-1 NAb was delivered (i.p.) 1 701 
day before challenging K18-hACE2 mice with 1 x 105 FFU of SARS-CoV-2 nLuc. Human IgG1-702 
treated (12.5 mg/kg) mice were used as control (isotype treated). Mice were followed by non-703 
invasive BLI every 2 days from the start of infection using IVIS Spectrum after retroorbital 704 
administration of furimazine (nLuc substrate).  705 
(B) SARS-CoV-2 replication and dissemination in K18-hACE2 transgenic mice (n = 4-6 per group) 706 
for experiment as in A, were monitored via BLI in ventral (v) and dorsal (d) positions at the 707 
indicated days post infection every 2 days. Images from two mice under CV3-1 prophylaxis (0.7 708 
mg/kg) are shown where one mouse succumbed at 6 dpi and the other survived despite weak but 709 
observable neuroinvasion. Images from one representative experiment are shown for the rest. 710 
(C-D) A plot showing temporal quantification of nLuc signal acquired non-invasively and displayed 711 
as photon flux (photons/sec) in whole body or brain region of SARS-CoV2-nLuc infected K18-712 
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprintthis version posted March 22, 2021. ; https://doi.org/10.1101/2021.03.22.436337doi: bioRxiv preprint 
31 
 
hACE2 mice for an experiment as in A. Each curve represents luminescent signal computed for 713 
individual mouse. Scale bars denote radiance in photons per second per square centimeter per 714 
steradian (p/sec/cm2/sr). 715 
(E) A plot showing temporal body weight changes in indicated groups of K18-hACE2 mice at 716 
indicated days post infection for an experiment shown in A. Each curve represents one animal. 717 
The body weight at the start of the experiment was set to 100 %.  718 
(F) Kaplan-Meier survival curves of mice statistically compared by log-rank (Mantel-Cox) test for 719 
experiment as in A. 720 
(G) Plot showing viral loads as nLuc activity per gram of indicated organs using Vero E6 cells as 721 
targets. Undetectable virus amounts were set to 1 for display on log plots. 722 
Grouped data in (C)-(E) and G were analyzed by 2-way ANOVA followed by Dunnett’s or Tukey’s 723 
multiple comparison tests. Statistical significance: group comparisons to isotype control are 724 
shown in black; group comparisons to CV3-1 (0.7 mg/kg) are shown in red. ∗, p < 0.05; ∗∗, p < 725 
0.01; ∗∗∗, p < 0.001; ∗∗∗∗, p < 0.0001; Mean values ± SD are depicted. 726 
 727 
Figure S5. LALA mutations Diminish Antibody Effector Functions of CV3-1 and CV3-25 728 
without Compromising Neutralizing Activity. Related to Figure 6. (A) Cell-surface staining 729 
of CEM.NKr cells stably expressing full-length SARS-CoV-2 Spike (CEM.NKr-Spike) using CV3-730 
1 and CV3-25 mAbs or their LALA mutant counterpart. The graph shown represent the mean 731 
fluorescence intensities (MFI) obtained. with titrated concentrations of anti-Spike NAbs. MFI 732 
values obtained with parental CEM.NKr were subtracted.  733 
(B) Pseudoviral particles encoding for the luciferase reporter gene and bearing the SARS-CoV-2 734 
S glycoproteins were used to infect 293T-ACE2 cells. Neutralizing activity was measured by 735 
incubating pseudoviruses with titrated concentrations of anti-Spike NAbs at 37°C for 1 h prior to 736 
infection of 293T-ACE2 cells. Neutralization half maximal inhibitory antibody concentration (IC50) 737 
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values were determined using a normalized non-linear regression using GraphPad Prism 738 
software.  739 
(C) Using a FACS-based ADCC assay, CEM.NKr parental cells were mixed at a 1:1 ratio 740 
with CEM.NKr-Spike cells and were used as target cells. PBMCs from uninfected donors were 741 
used as effector cells. The graph shown represent the percentages of ADCC obtained in the 742 
presence of titrated concentrations of anti-Spike NAbs.  743 
(D) Using a FACS-based ADCP assay, CEM.NKr-Spike cells were used as target cells and THP-744 
1 monocytic cell line was used as effector cells. The graph shown represent the percentages 745 
of effector cells that had phagocytosed target cells obtained in the presence of titrated 746 
concentrations of anti-Spike NAbs.  747 
Statistical significance was tested using a non-parametric Mann-Whitney test for pairwise 748 
comparison between WT and LALA NAbs (*, p < 0.05; **, p < 0.01; ns, not significant)  749 
(E-F) Biodistribution of CV3-25 and CV3-1 LALA mutants in mice 24 h after i.p. delivery. B6 mice 750 
were either isotype treated (control) or intraperitoneally administered of Alexa Fluor 647 751 
conjugated LALA mutants of CV3-25 or CV3-1 NAb mutants (12.5 mg/kg body weight). 24 h later, 752 
indicated tissues were imaged using the fluorescence module in IVIS spectrum to detect Alexa 753 
Flour 647. The plot shows the quantified radiance detected in indicated tissues after normalization 754 
with corresponding organs from control mouse.  755 
(G, H) Images of cryosections from brain tissues of K18-hACE2 mice pretreated with LALA 756 
mutants of CV3-25 or CV3-1 (i.p., 12.5 µg/g body weight) at 6 dpi. Actin was detected using 757 
phalloidin-Alexa Fluor 488. CV3-25 and CV3-1 (magenta) were detected using Alexa Fluor 647 758 
conjugated anti-human IgG respectively. Infected cells were detected using antibodies to SARS-759 
CoV-2 nucleocapsid (red). Images show penetration of both CV3-25 and CV3-1 mAbs into the 760 
brain and localization to the surface of infected neurons. Scale bar: 20 µm 761 
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(I) SARS-CoV-2 can establish infection in nasal cavity and lungs during CV3-1 prophylaxis. A 762 
scheme showing experimental design to test establishment of virus infection in K18-hACE2 mice 763 
pretreated with CV3-1 NAb (i.p.,12.5 mg/kg body weight), 1 day before challenging with 1 x 105 764 
FFU of SARS-CoV-2 nLuc. Mice treated similarly with Isotype matched hIgG1 were used as 765 
controls. The mice were followed by non-invasive BLI at 0 and 3 dpi using IVIS Spectrum after 766 
retroorbital administration of furimazine (nLuc substrate).  767 
(J) SARS-CoV-2 replication and dissemination in indicated groups of K18-hACE2 transgenic mice 768 
(n = 5-3 per group) for experiment as in I, were monitored via BLI at the indicated times. The mice 769 
were euthanized at 3 dpi and imaged again after necropsy. Images from one representative 770 
experiment are shown. 771 
(K) A plot showing temporal quantification of nLuc signal acquired non-invasively and displayed 772 
as photon flux (photons/sec) in whole body of SARS-CoV2-nLuc infected K18-hACE2 mice for an 773 
experiment as in I. Each line represents luminescent signal computed for individual mouse.  774 
 (L, M) Ex vivo imaging of indicated organs after necropsy at 3 dpi and quantification of nLuc 775 
signal displayed as photon flux (photons/sec) in K18-ACE2 mice for experiment as in I. 776 
(N) A plot showing real-time PCR analyses to detect SARS-CoV-2 nucleocapsid (N) gene mRNA 777 
in indicated organs of K18-hACE2 mice for an experiment as in I. The data were normalized to N 778 
gene mRNA seen in uninfected mice and Gapdh mRNA levels. Scale bars denote radiance 779 
(photons/sec/cm2/steradian). p values obtained by non-parametric Mann-Whitney test for pairwise 780 
comparison with isotype-treated controls; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; 781 
individual data points along with mean values ± SD are depicted.  782 
 783 
Figure S6. Fc-mediated Antibody Effector Functions Contribute to In Vivo Efficacy of CV3-784 
1 and CV3-25 During Prophylaxis. Related to Figure 6. (A) A scheme showing experimental 785 
design for testing in vivo efficacy of neutralizing antibody CV3-1, CV3-25 and their corresponding 786 
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Leucine to Alanine (LALA) mutants (12.5 mg/kg body weight) delivered intraperitoneally (i.p.) 1 787 
day before challenging K18-hACE2 mice with 1 x 105 FFU of SARS-CoV-2 nLuc. Human IgG1-788 
treated (12.5 mg/kg body weight) mice were used as control (Iso). Mice were followed by non-789 
invasive BLI every 2 days from the start of infection using IVIS Spectrum after retroorbital 790 
administration of furimazine (nLuc substrate).  791 
(B) SARS-CoV-2 replication and dissemination in K18-hACE2 transgenic mice (n = 4-8 per group) 792 
for experiment as in A, were monitored via BLI in ventral (v) and dorsal (d) positions at the 793 
indicated days post infection every 2 days. The mice were euthanized on indicated days and 794 
imaged again after necropsy. Images from one representative experiment are shown. 795 
(C-D) A plot showing temporal quantification of nLuc signal acquired non-invasively and displayed 796 
as Flux (photons/sec) in whole body or brain region of SARS-CoV2-nLuc infected K18-hACE2 797 
mice for an experiment as in A. Each curve represents luminescent signal computed for individual 798 
mouse.  799 
(E) A plot showing temporal body weight changes of K18-hACE2 mice at indicated days post 800 
infection for an experiment shown in A. Each curve represents one animal. The body weight at 801 
the start of the experiment was set to 100%.  802 
(F) Kaplan-Meier survival curves of mice statistically compared by log-rank (Mantel-Cox) test for 803 
experiment as in A. 804 
(G, H) Ex vivo imaging of indicated organs after necropsy at indicated dpi and quantification of 805 
nLuc signal displayed as Flux (photons/sec) in K18-ACE2 mice for experiment as in A. 806 
(I) Plot showing viral loads as nLuc activity per gram of indicated organs using Vero E6 cells as 807 
targets. Nluc activity was determined 24 h after infection. Undetectable virus amounts were set to 808 
1 for display on log plots. 809 
(J, K) A plot showing mRNA levels of indicated cytokines from lung and brain tissues of K18-810 
hACE2 mice at the time of euthanasia as shown in F. The mRNA amounts were normalized to 811 
the levels seen in uninfected mice and the house keeping gene Gapdh.  812 
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Scale bars in (B) and (G) denote radiance (photons/sec/cm2/steradian). Grouped data in (C)-(E) 813 
and (H)-(K) were analyzed by 2-way ANOVA followed by Dunnett’s or Tukey’s multiple 814 
comparison tests. Statistical significance: group comparisons to isotype control are shown in 815 
black; group comparisons between CV3-25 LALA and CV3-25 treated cohorts are shown in red; 816 
group comparison between CV3-1 LALA and CV3-1 treated cohorts are shown in purple. ∗, p < 817 
0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001; ∗∗∗∗, p < 0.0001; Mean values ± SD are depicted. 818 
 819 
Figure S7. NK Cells Contribute Marginally to In Vivo Efficacy During CV3-1 Prophylaxis. 820 
Related to Figure 7. (A) A scheme showing experimental design for testing the contribution of 821 
NK cells in K18-hACE2 mice pretreated with CV3-1 NAb (i.p.,12.5 mg/kg  body weight), 1 day 822 
before challenging with 1 x 105 FFU of SARS-CoV-2 nLuc. αNK1.1 mAb (i.p., 20 mg/kg body 823 
weight) was used to deplete NK cells at indicated time points. Corresponding human (for CV3-1) 824 
and rat (for αNK1.1) antibodies served as non-specific isotype controls. The mice were followed 825 
by non-invasive BLI every 2 days from the start of infection using IVIS Spectrum after retroorbital 826 
administration of furimazine (nLuc substrate).  827 
(B) SARS-CoV-2 replication and dissemination in indicated groups of K18-hACE2 transgenic mice 828 
(n = 5 per group) for experiment as in A, were monitored via BLI at ventral (v) and dorsal (d) 829 
positions at the indicated days post infection every 2 days. The mice were euthanized at indicated 830 
times and imaged again after necropsy. Images from one representative experiment are shown. 831 
(C-D) A plot showing temporal quantification of nLuc signal acquired non-invasively and displayed 832 
as photon flux (photons/sec) in whole body or brain region of SARS-CoV2-nLuc infected K18- 833 
hACE2 mice for an experiment as in A. Each curve represents luminescent signal computed for 834 
individual mouse. Scale bars denote radiance (photons/sec/cm2/steradian). 835 
(E) A plot showing temporal body weight changes in designated groups of K18-hACE2 mice at 836 
indicated days post infection for an experiment shown in A. Each curve represents one animal. 837 
The body weight at the start of the experiment was set to 100%.  838 
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(F) Kaplan-Meier survival curves of mice statistically compared by log-rank (Mantel-Cox) test for 839 
experiment as in A. 840 
(G) Plot showing viral loads as nLuc activity per gram of indicated organs using Vero E6 cells as 841 
targets. Nluc activity was determined 24 h after infection. Undetectable virus amounts were set to 842 
1 for display on log plots. 843 
(H, I) A plot showing mRNA levels of indicated cytokines from lung and brain tissues of K18-844 
hACE2 mice at the time of euthanasia as shown in F. The mRNA amounts were normalized to 845 
the levels seen in uninfected mice and the house keeping gene GAPDH.  846 
(J, K) Representative FACS plots showing the gating strategy to identify NK cells (CD3-NK1.1+) 847 
and quantification to ascertain their depletion in PBMCs of indicated groups of mice. 848 
(L, M) Representative FACS plots showing the gating strategy to identify neutrophils cells (CD45+ 849 
CD11b+Ly6G+) and quantification to ascertain their depletion in PBMCs of indicated groups of 850 
mice.  851 
(N, O) Representative FACS plots showing the gating strategy to identify Ly6Chi monocytes and 852 
quantification to ascertain their depletion in PBMCs of indicated groups of mice. 853 
Grouped data in (C)-(E) and (G)-(I) were analyzed by 2-way ANOVA followed by Dunnett’s or 854 
Tukey’s multiple comparison tests. Statistical significance: group comparisons to isotype control 855 
are shown in black; group comparisons to Iso+CV3-1 treated cohort are in red. Pairwise 856 
comparisons in (K), (M) and (O) were analyzed using non-parametric Mann-Whitney test. ∗, p < 857 
0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001; ∗∗∗∗, p < 0.0001; Mean values ± SD are depicted. 858 
 859 
Supplementary Multimedia Files: 860 
Video S1. Longitudinal Non-invasive BLI of SARS-CoV-2-nLuc infection and dissemination 861 
in K18-hACE2 mice, Related to Figure 1. SARS-CoV-2-nLuc challenged mice were imaged 862 
daily in dorsal (d) and ventral (v) positions for 6 days using IVIS Spectrum to monitor virus spread 863 
in the whole body as well as neuroinvasion. 864 
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Video S2. Tomographic Reconstruction of SARS-CoV-2 Infected Lung Tissue, Related to 866 
Figure S2, panels B-D. Virus particles are found within membrane-enclosed exit compartments 867 
of two adjacent pulmonary capillary endothelial cells.  The movie traverses the reconstructed 868 
volume to illustrate the compartments (red arrowheads) then increases in magnification to detail 869 
the virions within the compartments.  870 
Video S3. Tomographic Reconstruction of SARS-CoV-2 Infected Brain Tissue, Related to 871 
Figure S2, panel F. Virus particles are found within neurons, often appearing in linear groups 872 
within compartments bordering the edges of neuronal projections. The movie details the 873 
distinction between presumptive SARS-CoV-2 virions and typical synaptic neurotransmitter 874 
vesicles found in an adjacent synaptic terminal. 875 
 876 
Video S4. Tomographic Reconstruction of SARS-CoV-2 Infected Testis Tissue, Related to 877 
Figure S2, panel M. Virus particles are found within membrane-enclosed compartments of Sertoli 878 
cells. Additional material and structures coexist with the virions in these compartments, 879 
suggesting they may be defined as lysosomes. Presumptive SARS-CoV-2 virions can be 880 
discerned from the other structures.  881 
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RESOURCE AVAILABILITY 882 
Lead Contact 883 
Further information and requests for resources and reagents should be directed to and will be 884 
fulfilled by the Lead Contact, Pradeep Uchil (pradeep.uchil@yale.edu), Priti Kumar 885 
(priti.kumar@yale.edu), Andrés Finzi (andres.finzi@umontreal.ca) and Walther 886 
Mothes(walther.mothes@yale.edu). 887 
Materials Availability 888 
All other unique reagents generated in this study are available from the corresponding authors 889 
with a completed Materials Transfer Agreement. 890 
Data and Code Availability  891 
The data that support the findings of this study are available from the corresponding authors 892 
upon reasonable request. 893 
 894 
EXPERIMENTAL MODEL AND SUBJECT DETAILS  895 
 896 
Cell and Viruses  897 
Vero E6 (CRL-1586, American Type Culture Collection (ATCC), were cultured at 37°C in RPMI 898 
supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES pH 7.3, 1 mM sodium pyruvate, 899 
1× non-essential amino acids, and 100 U/ml of penicillin–streptomycin. The 2019n-900 
CoV/USA_WA1/2019 isolate of SARS-CoV-2 expressing nanoluciferase was obtained from Craig 901 
B Wilen, Yale University and generously provided by K. Plante and Pei-Yong Shi, World 902 
Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch) 903 
(Xie et al., 2020a; Xie et al., 2020b). The SARS-CoV-2 USA-WA1/2020 virus strain used for 904 
microneutralization assay was obtained through BEI Resources. Virus was propagated in Vero-905 
E6 by infecting them in T150 cm2 flasks at a MOI of 0.1. The culture supernatants were collected 906 
after 72 h when cytopathic effects were clearly visible. The cell debris was removed by 907 
centrifugation and filtered through 0.45-micron filter to generate virus stocks. Viruses were 908 
concentrated by adding one volume of cold (4 °C) 4x PEG-it Virus Precipitation Solution (40 % 909 
(w/v) PEG-8000 and 1.2 M NaCl; System Biosciences) to three volumes of virus-containing 910 
supernatant. The solution was mixed by inverting the tubes several times and then incubated at 911 
4 °C overnight. The precipitated virus was harvested by centrifugation at 1,500 × g for 60 minutes 912 
at 4 °C. The concentrated virus was then resuspended in PBS then aliquoted for storage at −80°C. 913 
All work with infectious SARS-CoV-2 was performed in Institutional Biosafety Committee 914 
approved BSL3 and A-BSL3 facilities at Yale University School of Medicine or the University of 915 
Western Ontario using appropriate positive pressure air respirators and protective equipment. 916 
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CEM.NKr, CEM.NKr-Spike, THP-1 and peripheral blood mononuclear cells (PBMCs) were 917 
maintained at 37°C under 5% CO2 in RPMI media, supplemented with 10% FBS and 100 U/mL 918 
penicillin/ streptomycin. 293T (or HEK293T), 293T-ACE2, CF2Th, TZM-bl and TZM-bl-ACE2 cells 919 
were maintained at 37°C under 5% CO2 in DMEM media, supplemented with 5% FBS and 100 920 
U/mL penicillin/ streptomycin. CEM.NKr (NIH AIDS Reagent Program) is a T lymphocytic cell line 921 
resistant to NK cell-mediated lysis. CEM.NKr-Spike stably expressing SARS-CoV-2 Spike were 922 
used as target cells in ADCC and ADCP assays (Anand et al., 2021a). THP-1 monocytic cell line 923 
(ATCC) was used as effector cells in the ADCP assay. PBMCs were obtained from healthy donor 924 
through leukapheresis and were used as effector cells in ADCC assay. 293T cells (obtained from 925 
ATCC) were derived from 293 cells, into which the simian virus 40 T-antigen was inserted. 293T-926 
ACE2 cells stably expressing human ACE2 is derived from 293T cells (Prevost et al., 2020). 927 
Cf2Th cells (obtained from ATCC) are SARS-CoV-2-resistant canine thymocytes and were used 928 
in the virus capture assay. TZM-bl (NIH AIDS Reagent Program) were derived from HeLa cells 929 
and were engineered to contain the Tat-responsive firefly luciferase reporter gene. For the 930 
generation of TZM-bl cells stably expressing human ACE2, transgenic lentiviruses were produced 931 
in 293T using a third-generation lentiviral vector system. Briefly, 293T cells were co-transfected 932 
with two packaging plasmids (pLP1 and pLP2), an envelope plasmid (pSVCMV-IN-VSV-G) and 933 
a lentiviral transfer plasmid coding for human ACE2 (pLenti-C-mGFP-P2A-Puro-ACE2) 934 
(OriGene). Forty-eight hours post-transfection, supernatant containing lentiviral particles was 935 
used to infect TZM-bl cells in presence of 5 µg/mL of polybrene. Stably transduced cells were 936 
enriched upon puromycin selection. TZM-bl-ACE2 cells were then cultured in medium 937 
supplemented with 2 mg/mL of puromycin (Millipore Sigma). 938 
 939 
Ethics statement 940 
PBMCs from healthy individuals as a source of effector cells in our ADCC assay were obtained 941 
under CRCHUM institutional review board (protocol #19.381). Research adhered to the standards 942 
indicated by the Declaration of Helsinki. All participants were adults and provided informed written 943 
consent prior to enrollment in accordance with Institutional Review Board approval. 944 
 945 
Antibodies 946 
The human antibodies (CV3-1 and CV3-25) used in the work were isolated from blood of male 947 
convalescent donor S006 (male) recovered 41 days after symptoms onset using fluorescent 948 
recombinant stabilized Spike ectodomains (S2P) as probes to identify antigen-specific B cells as 949 
previously described (Lu et al., 2020; Seydoux et al., 2020). Site-directed mutagenesis was 950 
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performed on plasmids expressing CV3-1 and CV3-25 antibody heavy chains in order to introduce 951 
the LALA mutations (L234A/L235A) using to the QuikChange II XL site-directed mutagenesis 952 
protocol (Stratagene). 953 
 954 
Mouse Experiments 955 
All experiments were approved by the Institutional Animal Care and Use Committees (IACUC) of 956 
and Institutional Biosafety Committee of Yale University (IBSCYU). All the animals were housed 957 
under specific pathogen-free conditions in the facilities provided and supported by Yale Animal 958 
Resources Center (YARC). All IVIS imaging, blood draw and virus inoculation experiments were 959 
done under anesthesia using regulated flow of isoflurane:oxygen mix to minimize pain and 960 
discomfort to the animals. 961 
C57BL/6 (B6), hACE2 transgenic B6 mice (heterozygous) were obtained from Jackson 962 
Laboratory. 6–8-week-old male and female mice were used for all the experiments. The 963 
heterozygous mice were crossed and genotyped to select heterozygous mice for experiments by 964 
using the primer sets recommended by Jackson Laboratory.  965 
 966 
METHOD DETAILS 967 
 968 
SARS-CoV-2 infection and treatment conditions 969 
 For all in vivo experiments, the 6 to 8 weeks male and female mice were intranasally challenged 970 
with 1 x 105 FFU in 25-30 µl volume under anesthesia (0.5 - 5 % isoflurane delivered using 971 
precision Dräger vaporizer with oxygen flow rate of 1 L/min). For NAb treatment using prophylaxis 972 
regimen, mice were treated with 250 µg (12.5 mg/kg body weight) of indicated antibodies (CV3-1 973 
or CV3-25) or in combination (1:1; 6.25 mg/kg body weight of each) via intraperitoneal injection 974 
(i.p.) 24 h prior to infection. For mAb treatment under therapeutic regimen, mice were treated at 975 
1, 3 and 4 dpi intraperitoneally with CV3-1(12.5 mg/kg body weight). Body weight was measured 976 
and recorded daily. The starting body weight was set to 100 %. For survival experiments, mice 977 
were monitored every 6-12 h starting six days after virus administration. Lethargic and moribund 978 
mice or mice that had lost more than 20% of their body weight were sacrificed and considered to 979 
have succumbed to infection for Kaplan-Meier survival plots. 980 
 981 
Bioluminescence Imaging (BLI) of SARS-CoV-2 infection 982 
All standard operating procedures and protocols for IVIS imaging of SARS-CoV-2 infected 983 
animals under ABSL-3 conditions were approved by IACUC, IBSCYU and YARC. All the imaging 984 
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was carried out using IVIS Spectrum® (PerkinElmer) in XIC-3 animal isolation chamber 985 
(PerkinElmer) that provided biological isolation of anesthetized mice or individual organs during 986 
the imaging procedure. All mice were anesthetized via isoflurane inhalation (3 - 5 % isoflurane, 987 
oxygen flow rate of 1.5 L/min) prior and during BLI using the XGI-8 Gas Anesthesia System. Prior 988 
to imaging, 100 µL of nanoluciferase substrate, furimazine (NanoGloTM, Promega, Madison, WI) 989 
diluted 1:40 in endotoxin-free PBS was retroorbitally administered to mice under anesthesia. The 990 
mice were then placed into XIC-3 animal isolation chamber (PerkinElmer) pre-saturated with 991 
isothesia and oxygen mix. The mice were imaged in both dorsal and ventral position at indicated 992 
days post infection. The animals were then imaged again after euthanasia and necropsy by 993 
spreading additional 200 µL of substrate on to exposed intact organs. Infected areas of interest 994 
identified by carrying out whole-body imaging after necropsy were isolated, washed in PBS to 995 
remove residual blood and placed onto a clear plastic plate. Additional droplets of furimazine in 996 
PBS (1:40) were added to organs and soaked in substrate for 1-2 min before BLI. 997 
 Images were acquired and analyzed with the manufacturer’s Living Image v4.7.3 in vivo 998 
software package. Image acquisition exposures were set to auto, with imaging parameter 999 
preferences set in order of exposure time, binning, and f/stop, respectively. Images were acquired 1000 
with luminescent f/stop of 2, photographic f/stop of 8. Binning was set to medium. Comparative 1001 
images were compiled and batch-processed using the image browser with collective luminescent 1002 
scales. Photon flux was measured as luminescent radiance (p/sec/cm2/sr). During luminescent 1003 
threshold selection for image display, luminescent signals were regarded as background when 1004 
minimum threshold levels resulted in displayed radiance above non-tissue-containing or known 1005 
uninfected regions. To determine the pattern of virus spread, the image sequences were acquired 1006 
every day following administration of SARS-CoV-2 (i.n). Image sequences were assembled and 1007 
converted to videos using Image J. 1008 
 1009 
Biodistribution of therapeutic neutralizing antibodies using IVIS  1010 
Mice were intraperitoneally (i.p) administered with 250 µg of unconjugated (12.5 mg/kg body 1011 
weight), Alexa Fluor 647 or Alexa Fluor 594-labeled antibodies to non-infected or SARS-CoV-2 1012 
infected hACE2 mice. 24 h later all organs (nose, trachea, lung, cervical lymph nodes, brain, liver, 1013 
spleen, kidney, gut, testis and seminal vesicles) were isolated after necropsy and images were 1014 
acquired with an IVIS Spectrum® (PerkinElmer) and fluorescence radiance intensities were 1015 
analyzed with the manufacturer’s Living Image v4.7.3 in vivo software package. Organs were cut 1016 
into half and weighed. One half was fixed in 4 % PFA and processed for cryoimmunohistology. 1017 
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The other half was resuspended in serum-free RPMI and homogenized in a bead beater for 1018 
determination of antibody levels using quantitative ELISA. 1019 
 1020 
Measurement of therapeutic antibody levels in organs by quantitative ELISA 1021 
Recombinant SARS-CoV-2 RBD and S-6P proteins were used to quantify CV3-1 and CV3-25 1022 
antibody levels, respectively, in mice organs. SARS-CoV-2 proteins (2.5 μg/ml), or bovine serum 1023 
albumin (BSA) (2.5 μg/ml) as a negative control, were prepared in PBS and were adsorbed to 1024 
plates (MaxiSorp; Nunc) overnight at 4 °C. Coated wells were subsequently blocked with blocking 1025 
buffer (Tris-buffered saline [TBS], 0.1% Tween20, 2% BSA) for 1 hour at room temperature. Wells 1026 
were then washed four times with washing buffer (TBS 0.1% Tween20). Titrated concentrations 1027 
of CV3-1 or CV3-25 or serial dilutions of mice organ homogenates were prepared in a diluted 1028 
solution of blocking buffer (0.1 % BSA) and incubated in wells for 90 minutes at room temperature. 1029 
Plates were washed four times with washing buffer followed by incubation with HRP-conjugated 1030 
anti-IgG secondary Abs (Invitrogen) (diluted in a diluted solution of blocking buffer [0.4% BSA]) 1031 
for 1 hour at room temperature, followed by four washes. HRP enzyme activity was determined 1032 
after the addition of a 1:1 mix of Western Lightning oxidizing and luminol reagents (Perkin Elmer 1033 
Life Sciences). Light emission was measured with a LB941 TriStar luminometer (Berthold 1034 
Technologies). Signal obtained with BSA was subtracted for each organ. Titrated concentrations 1035 
of CV3-1 or CV3-25 were used to establish a standard curve of known antibody concentrations 1036 
and the linear portion of the curve was used to infer the antibody concentration in tested organ 1037 
homogenates.  1038 
 1039 
Cryo-immunohistology of organs 1040 
Organs were isolated after necropsy and fixed in 1X PBS containing freshly prepared 4% PFA for 1041 
12 h at 4 °C. They were then washed with PBS, cryoprotected with 10, 20 and 30% ascending 1042 
sucrose series, snap-frozen in Tissue-Tek® O.C.T.TM compound and stored at -80 °C. The nasal 1043 
cavity was snap-frozen in 8% gelatin prepared in 1X PBS and stored at -80 °C. 10 - 30 µm thick 1044 
frozen sections were permeabilized with Triton X-100 and treated with Fc receptor blocker 1045 
(Innovex Biosciences) before staining with indicated conjugated primary, secondary antibodies or 1046 
Phalloidin in PBS containing 2 % BSA containing 10 % fetal bovine serum. Stained sections were 1047 
treated with TrueVIEW Autofluorescence Quenching Kit (Vector Laboratories) and mounted in 1048 
VECTASHIELD® Vibrance™ Antifade Mounting Medium. Images were acquired using Nikon W1 1049 
spinning disk confocal microscope equipped with 405, 488, 561 and 647 nm laser lines. The 1050 
images were processed using Nikon Elements AR version 4.5 software (Nikon Instruments Inc, 1051 
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Americas) and figures assembled with Photoshop CC and Illustrator CC (Adobe Systems, San 1052 
Jose, CA, USA). 1053 
 1054 
Focus forming assay  1055 
Titers of virus stocks was determined by standard plaque assay. Briefly, the 4 x 105 Vero-E6 cells 1056 
were seeded on 12-well plate. 24 h later, the cells were infected with 200 µL of serially diluted 1057 
virus stock. After 1 hour, the cells were overlayed with 1ml of pre-warmed 0.6% Avicel (RC-581 1058 
FMC BioPolymer) made in complete RPMI medium. Plaques were resolved at 48 h post infection 1059 
by fixing in 10 % paraformaldehyde for 15 min followed by staining for 1 hour with 0.2 % crystal 1060 
violet made in 20 % ethanol. Plates were rinsed in water to visualize plaques. 1061 
 1062 
Measurement of viral burden 1063 
Indicated organs (nasal cavity, brain, lungs from infected or uninfected mice were collected, 1064 
weighed, and homogenized in 1 mL of serum free RPMI media containing penicillin-streptomycin 1065 
and homogenized in 2 mL tube containing 1.5 mm Zirconium beads with BeadBug 6 homogenizer 1066 
(Benchmark Scientific, TEquipment Inc). Virus titers were measured using three highly correlative 1067 
methods. Frist, the total RNA was extracted from homogenized tissues using RNeasy plus Mini 1068 
kit (Qiagen Cat # 74136), reverse transcribed with iScript advanced cDNA kit (Bio-Rad Cat 1069 
#1725036) followed by a SYBR Green Real-time PCR assay for determining copies of SARS-1070 
CoV-2 N gene RNA using primers SARS-CoV-2 N F: 5’-ATGCTGCAATCGTGCTACAA-3’ and 1071 
SARS-CoV-2 N R: 5’-GACTGCCGCCTCTGCTC-3’. 1072 
Second, serially diluted clarified tissue homogenates were used to infect Vero-E6 cell culture 1073 
monolayer. The titers per gram of tissue were quantified using standard plaque forming assay 1074 
described above. Third, we used nanoluciferase activity as a shorter surrogate for plaque assay. 1075 
Infected cells were washed with PBS and then lysed using 1X Passive lysis buffer. The lysates 1076 
transferred into a 96-well solid white plate (Costar Inc) and nanoluciferase activity was measured 1077 
using Tristar multiwell Luminometer (Berthold Technology, Bad Wildbad, Germany) for 2.5 1078 
seconds by adding 20 µl of Nano-Glo® substrate in nanoluc assay buffer (Promega Inc, WI, USA). 1079 
Uninfected monolayer of Vero cells treated identically served as controls to determine basal 1080 
luciferase activity to obtain normalized relative light units. The data were processed and plotted 1081 
using GraphPad Prism 8 v8.4.3.  1082 
 1083 
Analyses of signature inflammatory cytokines mRNA  1084 
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Brain and lung samples were collected from mice at the time of necropsy. Approximately, 20 mg 1085 
of tissue was suspended in 500 µL of RLT lysis buffer, and RNA was extracted using RNeasy 1086 
plus Mini kit (Qiagen Cat # 74136), reverse transcribed with iScript advanced cDNA kit (Bio-Rad 1087 
Cat #1725036). To determine levels of signature inflammatory cytokines, multiplex qPCR was 1088 
conducted using iQ Multiplex Powermix (Bio Rad Cat # 1725848) and PrimePCR Probe Assay 1089 
mouse primers FAM-GAPDH, HEX-IL6, TEX615-CCL2, Cy5-CXCL10, and Cy5.5-IFNgamma. 1090 
The reaction plate was analyzed using CFX96 touch real time PCR detection system. Scan mode 1091 
was set to all channels. The PCR conditions were 95 °C 2 min, 40 cycles of 95 °C for 10 s and 1092 
60 °C for 45 s, followed by a melting curve analysis to ensure that each primer pair resulted in 1093 
amplification of a single PCR product. mRNA levels of Il6, Ccl2, Cxcl10 and Ifng in the cDNA 1094 
samples of infected mice were normalized to Gapdh with the formula ΔCt(target gene)=Ct(target 1095 
gene)-Ct(Gapdh). The fold increase was determined using 2-ΔΔCt method comparing treated mice 1096 
to uninfected controls.  1097 
 1098 
Antibody depletion of immune cell subsets  1099 
For evaluating the effect of NK cell depletion during CV3-1 prophylaxis, anti-NK1.1 (clone PK136; 1100 
12.5 mg/kg body weight) or an isotype control mAb (BioXCell; clone C1.18.4; 12.5 mg/kg body 1101 
weight) was administered to mice by i.p. injections every 2 days starting at 48 h before SARS-1102 
CoV-2-nLuc challenge till 8 dpi. The mice were bled after two days of antibody depletion, necropsy 1103 
or at 10 dpi (surviving mice) for analyses. To evaluate the effect of NK cell and neutrophil depletion 1104 
during CV3-1 therapy, anti-NK1.1 (clone PK136; 12.5 mg/kg body weight) or anti-Ly6G (clone: 1105 
1A8; 12.5 mg/kg body weight) was administered to mice by i.p injection every two days starting 1106 
at 1 dpi respectively. Rat IgG2a mAb (BioXCell; clone C1.18.4; 12.5 mg/kg body weight) was 1107 
used as isotype control. The mice were sacrificed and bled at 10 dpi for analyses. For evaluating 1108 
the effect of monocyte depletion on CV3-1 therapy, anti-CCR2 (clone MC-21; 2.5 mg/kg body 1109 
weight) (Mack et al., 2001) or an isotype control mAb (BioXCell; clone LTF-2; 2.5 mg/kg body 1110 
weight) was administered to mice by i.p injection every two days starting at 1 dpi. The mice were 1111 
sacrificed and bled 2-3 days after antibody administration or at 10 dpi to ascertain depletion of 1112 
desired population. 1113 
 1114 
Flow Cytometric Analyses 1115 
 For analysis of immune cell depletion, peripheral blood was collected before infection and on day 1116 
of harvest. Erythrocytes were lysed with RBC lysis buffer (BioLegend Inc), PBMCs fixed with 4 % 1117 
PFA and quenched with PBS containing 0.1M glycine. PFA-fixed cells PBMCs were resuspended 1118 
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and blocked in Cell Staining buffer (BioLegend Inc.) containing Fc blocking antibody against 1119 
CD16/CD32 (BioLegend Inc) before staining with antibodies. NK cells were identified as CD3-1120 
NK1.1+ cells using PE/Cy7 anti-mouse CD3(17A2) and APC anti-mouse NK-1.1 (PK136). 1121 
Neutrophils were identified as CD45+CD11b+Ly6G+ cells using APC Rat anti-mouse CD45 (30-1122 
F11), PE anti-mouse CD11b (M1/70) APC/Cy7 and anti-mouse Ly-6G (1A8). Ly6Chi monocytes 1123 
were identified as CD45+CD11b+Ly6Chi cells using APC Rat anti-mouse CD45 (30-F11), PE anti-1124 
mouse CD11b (M1/70) and APC/Cy7 anti-mouse Ly-6C (HK1.4). Data were acquired on an Accuri 1125 
C6 (BD Biosciences) and were analyzed with Accuri C6 software. FlowJo software (Treestar) was 1126 
used to generate FACS plot shown in Figure S7. 100,000 – 200,000 viable cells were acquired 1127 
for each sample.  1128 
 1129 
Sample Preparation for Electron Microscopy  1130 
Lung, brain and testis tissue samples from hACE2 transgenic mice challenged intranasally with 1131 
SARS-CoV-2-nLuc (1 x 105 FFU; 6 dpi) were imaged after necropsy using bioluminescence 1132 
imaging (IVIS, Perkin Elmer), pruned to isolate regions with high nLuc activity and immediately 1133 
pre-fixed with 3 % glutaraldehyde, 1 % paraformaldehyde, 5 % sucrose in 0.1 M sodium 1134 
cacodylate trihydrate to render them safe for handling outside of BSL3 containment. Viral 1135 
infections of cultured cells were conducted at the UVM BSL-3 facility using an approved 1136 
Institutional Biosafety protocol. SARS-CoV-2 strain 2019-nCoV/USA_USA-WA1/2020 (WA1; 1137 
generously provided by K. Plante, World Reference Center for Emerging Viruses and 1138 
Arboviruses, University of Texas Medical Branch) and propagated in African green monkey kidney 1139 
(Vero E6) cells. Vero E6 cells were maintained in complete Dulbecco's Modified Eagle Medium 1140 
(DMEM; Thermo Fisher, Cat. #11965–092) containing 10% fetal bovine serum (Gibco, Thermo-1141 
Fisher, Cat. #16140–071), 1% HEPES Buffer Solution (15630–130), and 1 % penicillin–1142 
streptomycin (Thermo Fisher, Cat. #15140–122). Cells were grown in a humidified incubator at 1143 
37 ºC with 5 % CO2. Vero E6 cells were seeded into six well dishes and infected with SARS-CoV-1144 
2 at a multiplicity of infection of 0.01 for 48 hours before fixing and preparing for electron 1145 
microscopy. Cells were pre-fixed with 3% glutaraldehyde, 1% paraformaldehyde, 5 % sucrose in 1146 
0.1M sodium cacodylate trihydrate, removed from the plates and further prepared by high-1147 
pressure freezing and freeze-substitution as described below. 1148 
Tissues samples were further cut to ~0.5 mm3 blocks and cultured cells were gently pelleted.  1149 
Both samples were rinsed with fresh cacodylate buffer and placed into brass planchettes (Type 1150 
A; Ted Pella, Inc., Redding, CA) prefilled with 10 % Ficoll in cacodylate buffer. The tissues were 1151 
covered with the flat side of a Type-B brass planchette and rapidly frozen with an HPM-010 high-1152 
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pressure freezing machine (Leica Microsystems, Vienna Austria). The frozen samples were 1153 
transferred under liquid nitrogen to cryotubes (Nunc) containing a frozen solution of 2.5 % osmium 1154 
tetroxide, 0.05 % uranyl acetate in acetone. Tubes were loaded into an AFS-2 freeze-substitution 1155 
machine (Leica Microsystems) and processed at -90°C for 72 h, warmed over 12 h to -20°C, held 1156 
at that temperature for 6 h, then warmed to 4°C for 2 h. The fixative was removed, and the 1157 
samples rinsed 4 x with cold acetone, following which they were infiltrated with Epon-Araldite 1158 
resin (Electron Microscopy Sciences, Port Washington PA) over 48 h. The spleen tissue was flat-1159 
embedded between two Teflon-coated glass microscope slides.  Resin was polymerized at 60°C 1160 
for 48 h.  1161 
 1162 
Electron Microscopy and Dual-Axis Tomography 1163 
Flat-embedded tissue samples or portions of cell pellets were observed with a stereo dissecting 1164 
microscope and appropriate regions were extracted with a microsurgical scalpel and glued to the 1165 
tips of plastic sectioning stubs. Semi-thin (150-200 nm) serial sections were cut with a UC6 1166 
ultramicrotome (Leica Microsystems) using a diamond knife (Diatome, Ltd. Switzerland). Sections 1167 
were placed on formvar-coated copper-rhodium slot grids (Electron Microscopy Sciences) and 1168 
stained with 3 % uranyl acetate and lead citrate. Gold beads (10 nm) were placed on both surfaces 1169 
of the grid to serve as fiducial markers for subsequent image alignment. Sections were placed in 1170 
a dual-axis tomography holder (Model 2040, E.A. Fischione Instruments, Export PA) and imaged 1171 
with a Tecnai T12-G2 transmission electron microscope operating at 120 KeV (ThermoFisher 1172 
Scientific) equipped with a 2k x 2k CCD camera (XP1000; Gatan, Inc. Pleasanton CA). 1173 
Tomographic tilt-series and large-area montaged overviews were acquired automatically using 1174 
the SerialEM software package (Mastronarde, 2005, 2008; Mastronarde and Held, 2017). For 1175 
tomography, samples were tilted +/- 62° and images collected at 1° intervals. The grid was then 1176 
rotated 90° and a similar series taken about the orthogonal axis. Tomographic data was 1177 
calculated, analyzed, and modeled using the IMOD software package (Mastronarde, 2005, 2008; 1178 
Mastronarde and Held, 2017) on iMac Pro and MacPro computers (Apple, Inc., Cupertino, CA). 1179 
Montaged projection overviews were used to illustrate spatial perspective, identify cell types and 1180 
frequency within the tissue sections. High-resolution 3D electron tomography was used to confirm 1181 
virus particles and characterize virus-containing compartments within infected cells.  1182 
 1183 
Identification and Characterization of SARS-CoV-2 Virions in infected cells and tissues. 1184 
Particles resembling virions were examined in 3D by tomography to determine their identity. 1185 
Presumptive SARS-CoV-2 virions were identified from tomographic reconstructions of tissue 1186 
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samples by observing structures resembling virions described in cryo-electron tomography 1187 
studies of purified SARS-CoV-2 and of SARS-CoV-2 in infected cells (Ke et al., 2020; Klein et al., 1188 
2020; Turonova et al., 2020; Yao et al., 2020). These were compared to identified virions within 1189 
SARS-CoV-2–infected cultured Vero E6 cells that had been prepared for EM by the same 1190 
methodology (Figure 2O-Q). We used the following criteria to positively identify SARS-CoV-2 1191 
virions in tissues: (i) Structures that were spherical in 3D with ~60-120 nM diameters and were 1192 
not continuous with other adjacent structures, (ii) Spherical structures with densities 1193 
corresponding to a distinct membrane bilayer, internal puncta consistent with ribonucleoproteins 1194 
(Yao et al., 2020), and densities corresponding to surface spikes on the external peripheries of 1195 
the spheres. In further characterization of virions, we noted that the inner vesicles of multivesicular 1196 
bodies (MVBs) have been mis-identified as SARS-CoV-2 by electron microscopy (Calomeni et 1197 
al., 2020). We therefore compared measurements of MVB inner vesicles and presumptive 1198 
coronavirus virions from what we identified as intracellular exit compartments within the same 1199 
tomogram (data not shown) with our previous tomographic reconstructions of MVBs (He et al., 1200 
2008; Ladinsky et al., 2012). We distinguished virions inside of cytoplasmic exit compartments 1201 
from the inner vesicles of MVBs based on differences in size (MVB inner virions are generally 1202 
smaller in diameter than coronaviruses) and the presence of surface spikes and internal puncta 1203 
(MVB inner vesicles do not present surface spikes or internal puncta). 1204 
Immunoelectron microscopy. 1205 
SARS-CoV-2 infected tissues were extracted and immediately fixed with 4% paraformaldehyde, 1206 
5% sucrose in 0.1M cacodylate buffer.  Tissues were cut into ~0.5 mm3 pieces and infiltrated into 1207 
2.1M sucrose in 0.1M cacodylate buffer for 24 h.  Individual tissue pieces were placed onto 1208 
aluminum cryosectioning stubs (Ted Pella, Inc.) and rapidly frozen in liquid nitrogen. Thin (100 1209 
nm) cryosections were cut with a UC6/FC6 cryoultramicrotome (Leica Microsystems) using a 1210 
cryo-diamond knife (Diatome, Ltd., Switzerland) at -110°C.  Sections were picked up with a wire 1211 
loop in a drop of 2.3M sucrose in 0.1M cacodylate buffer and transferred to Formvar-coated, 1212 
carbon-coated, glow-discharged 100-mesh copper/rhodium grids (Electron Microscopy 1213 
Sciences). Grids were incubated 1 hr with 10% calf serum in PBS to block nonspecific antibody 1214 
binding, then incubated 2 hrs with anti-S antiserum (Cohen et al., 2021). Mosaic nanoparticles 1215 
elicit cross-reactive immune responses to zoonotic coronaviruses in mice (Cohen et al., 2021). 1216 
diluted 1:500 in PBS with 5% calf serum. Grids were rinsed (4x 10’) with PBS then labeled for 2 1217 
hrs with 10 nm gold conjugated goat anti-mouse secondary antibody (Ted Pella, Inc.). Grids were 1218 
again rinsed (4x 10’) with PBS, then 3x with distilled water and negatively stained with 1% uranyl 1219 
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprintthis version posted March 22, 2021. ; https://doi.org/10.1101/2021.03.22.436337doi: bioRxiv preprint 
48 
 
acetate in 1% methylcellulose (Sigma) for 20’. Grids were air-dried in wire loops and imaged as 1220 
described for ET. 1221 
 1222 
Protein expression and purification 1223 
FreeStyle 293F cells (Thermo Fisher Scientific) were grown in FreeStyle 293F medium (Thermo 1224 
Fisher Scientific) to a density of 1x106 cells/mL at 37°C with 8% CO2 with regular agitation (150 1225 
rpm). Cells were transfected with a plasmid coding for recombinant stabilized SARS-CoV-2 1226 
ectodomain (S-6P; obtained from Dr. Jason S. McLellan) or SARS-CoV-2 RBD (Beaudoin-1227 
Bussieres et al., 2020) using ExpiFectamine 293 transfection reagent, as directed by the 1228 
manufacturer (Thermo Fisher Scientific). One-week post-transfection, supernatants were clarified 1229 
and filtered using a 0.22 µm filter (Thermo Fisher Scientific). The recombinant S-6P was purified 1230 
by strep-tactin resin (IBA) following by size-exclusion chromatography on Superose 6 10/300 1231 
column (GE Healthcare) in 10 mM Tris pH 8.0 and 200 mM NaCl (SEC buffer). RBD was purified 1232 
by Ni-NTA column (Invitrogen) and gel filtration on Hiload 16/600 Superdex 200pg using the same 1233 
SEC buffer. Purified proteins were snap-frozen at liquid nitrogen and stored in aliquots at 80°C 1234 
until further use. Protein purities were confirmed as one single-band on SDS-PAGE. 1235 
 1236 
SARS-CoV-2 Spike ELISA (enzyme-linked immunosorbent assay) 1237 
The SARS-CoV-2 Spike ELISA assay used was recently described (Beaudoin-Bussieres et al., 1238 
2020; Prevost et al., 2020). Briefly, recombinant SARS-CoV-2 S-6P and RBD proteins (2.5 μg/ml), 1239 
or bovine serum albumin (BSA) (2.5 μg/ml) as a negative control, were prepared in PBS and were 1240 
adsorbed to plates (MaxiSorp; Nunc) overnight at 4 °C. Coated wells were subsequently blocked 1241 
with blocking buffer (Tris-buffered saline [TBS] containing 0.1% Tween20 and 2% BSA) for 1 hour 1242 
at room temperature. Wells were then washed four times with washing buffer (TBS containing 1243 
0.1% Tween20). CV3-1, CV3-25 and CR3022 mAbs (50 ng/ml) were prepared in a diluted solution 1244 
of blocking buffer (0.1 % BSA) and incubated with the RBD-coated wells for 90 minutes at room 1245 
temperature. Plates were washed four times with washing buffer followed by incubation with HRP-1246 
conjugated anti-IgG secondary Abs (Invitrogen) (diluted in a diluted solution of blocking buffer 1247 
[0.4% BSA]) for 1 hour at room temperature, followed by four washes. HRP enzyme activity was 1248 
determined after the addition of a 1:1 mix of Western Lightning oxidizing and luminol reagents 1249 
(Perkin Elmer Life Sciences). Light emission was measured with a LB941 TriStar luminometer 1250 
(Berthold Technologies). Signal obtained with BSA was subtracted for each plasma and was then 1251 
normalized to the signal obtained with CR3022 mAb present in each plate. 1252 
 1253 
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Flow cytometry analysis of cell-surface Spike staining.  1254 
Spike expressors of human coronaviruses SARS-CoV-2, SARS-CoV-1, MERS-CoV, OC43, NL63 1255 
and 229E were reported elsewhere (Hoffmann et al., 2020; Hoffmann et al., 2013; Hofmann et 1256 
al., 2005; Park et al., 2016; Prevost et al., 2020). Expressors of HKU1 Spike and SARS-CoV-2 1257 
S2 N-His were purchased from Sino Biological. Using the standard calcium phosphate method, 1258 
10 μg of Spike expressor and 2 μg of a green fluorescent protein (GFP) expressor (pIRES2-1259 
eGFP) was transfected into 2 × 106 293T cells. At 48 hours post transfection, 293T cells were 1260 
stained with CV3-1 and CV3-25 antibodies (5μg/mL), using cross-reactive anti-SARS-CoV-1 1261 
Spike CR3022 or mouse anti-His tag (Sigma-Aldrich) as positive controls. Alexa Fluor-647-1262 
conjugated goat anti-human IgG (H+L) Abs (Invitrogen) and goat anti-mouse IgG (H+L) Abs 1263 
(Invitrogen) were used as secondary antibodies. The percentage of transfected cells (GFP+ cells) 1264 
was determined by gating the living cell population based on the basis of viability dye staining 1265 
(Aqua Vivid, Invitrogen). Samples were acquired on a LSRII cytometer (BD Biosciences) and data 1266 
analysis was performed using FlowJo v10 (Tree Star).  1267 
 1268 
Virus capture assay 1269 
The SARS-CoV-2 virus capture assay was previously reported (Ding et al., 2020). Briefly, 1270 
pseudoviral particles were produced by transfecting 2×106 HEK293T cells with pNL4.3 Luc R-E- 1271 
(3.5 μg), plasmids encoding for SARS-CoV-2 Spike or SARS-CoV-1 Spike (3.5 μg) protein and 1272 
VSV-G (pSVCMV-IN-VSV-G, 1 μg) using the standard calcium phosphate method. Forty-eight 1273 
hours later, supernatant-containing virion was collected, and cell debris was removed through 1274 
centrifugation (1,500 rpm for 10 min). To immobilize antibodies on ELISA plates, white MaxiSorp 1275 
ELISA plates (Thermo Fisher Scientific) were incubated with 5 μg/ml of antibodies in 100 μl 1276 
phosphate-buffered saline (PBS) overnight at 4°C. Unbound antibodies were removed by 1277 
washing the plates twice with PBS. Plates were subsequently blocked with 3% bovine serum 1278 
albumin (BSA) in PBS for 1 hour at room temperature. After two washes with PBS, 200 μl of virus-1279 
containing supernatant was added to the wells. After 4 to 6 hours incubation, supernatants were 1280 
removed and the wells were washed with PBS 3 times. Virus capture by any given antibody was 1281 
visualized by adding 1×104 SARS-CoV-2-resistant Cf2Th cells per well in complete DMEM 1282 
medium. Forty-eight hours post-infection, cells were lysed by the addition of 30 μL of passive lysis 1283 
buffer (Promega) and three freeze-thaw cycles. An LB941 TriStar luminometer (Berthold 1284 
Technologies) was used to measure the luciferase activity of each well after the addition of 100 1285 
μL of luciferin buffer (15 mM MgSO4, 15 mM KH2PO4 [pH 7.8], 1 mM ATP, and 1 mM dithiothreitol) 1286 
and 50 μL of 1 mM D-luciferin potassium salt (ThermoFisher Scientific). 1287 
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Surface plasmon resonance (SPR) 1288 
All surface plasma resonance assays were performed on a Biacore 3000 (GE Healthcare) with a 1289 
running buffer of 10 mM HEPES pH 7.5 and 150 mM NaCl, supplemented with 0.05% Tween 20 1290 
at 25°C. The binding affinity and kinetics to the SARS-CoV-2 spike (S) trimer (SARS-CoV-2 S 1291 
HexaPro [S-6P]) (Hsieh et al., 2020) and SARS-CoV-2 S2 ectodomain (baculovirus produced his-1292 
tagged S2(686-1213) from BEI Resources (NR-53799) were evaluated using monovalent CV3-1 1293 
and CV3-25 Fab. Fabs were generated by standard papain digestion (Thermo Fisher) and purified 1294 
by Protein A affinity chromatography and gel filtration. His-tagged SARS-CoV-2 S-6P or SARS-1295 
CoV-2 S2 ectodomain was immobilized onto a Ni-NTA sensor chip at a level of ~1000 and ~630 1296 
RU response units (RUs), respectively. Two-fold serial dilutions of CV3-1 or CV3-25 Fab were 1297 
injected in a concentration range of 1.56-100 nM over the SARS-CoV-2 S-6P and CV3-25 Fab in 1298 
a range of 3.125 to 200 to nM over the SARS-CoV-2 S2. After each cycle the Ni-NTA sensor chip 1299 
was regenerated with a wash step of 0.1 M EDTA and reloaded with 0.1 M nickel sulfate followed 1300 
by the immobilization of fresh antigens for the next cycle. The binding kinetics of SARS-CoV-2 1301 
RBD and CV3-1 were obtained in a format where CV3-1 IgG was immobilized onto a Protein A 1302 
sensor chip (Cytiva) with ~300 (RUs) and serial dilutions of SARS-CoV-2 RBD were injected with 1303 
concentrations ranging from 1.56 to 50 nM. The protein A chip was regenerated with a wash step 1304 
of 0.1 M glycine pH 2.0 and reloaded with IgG after each cycle. 1305 
All sensograms were corrected by subtraction of the corresponding blank channel and the kinetic 1306 
constant determined using a 1:1 Langmuir model with the BIA evaluation software (GE 1307 
Healthcare). Goodness of fit of the curve was evaluated by the Chi2 value with a value below 3 1308 
considered acceptable  1309 
 1310 
Pseudovirus neutralization assay 1311 
Target cells were infected with single-round luciferase-expressing lentiviral particles. Briefly, 293T 1312 
cells were transfected by the calcium phosphate method with the pNL4.3 R-E- Luc plasmid (NIH 1313 
AIDS Reagent Program) and a plasmid encoding for SARS-CoV-2 Spike at a ratio of 5:4. Two 1314 
days post-transfection, cell supernatants were harvested and stored at –80°C until use. 293T-1315 
ACE2 (Prevost et al., 2020) target cells were seeded at a density of 1 × 104 cells/well in 96-well 1316 
luminometer-compatible tissue culture plates (Perkin Elmer) 24 h before infection. Recombinant 1317 
viruses in a final volume of 100 μL were incubated with the indicated semi-log diluted antibody 1318 
concentrations for 1 h at 37°C and were then added to the target cells followed by incubation for 1319 
48 h at 37°C; cells were lysed by the addition of 30 μL of passive lysis buffer (Promega) followed 1320 
by one freeze-thaw cycle. An LB941 TriStar luminometer (Berthold Technologies) was used to 1321 
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measure the luciferase activity of each well after the addition of 100 μL of luciferin buffer (15 mM 1322 
MgSO4, 15 mM KH2PO4 [pH 7.8], 1 mM ATP, and 1 mM dithiothreitol) and 50 μL of 1 mM d-1323 
luciferin potassium salt. The neutralization half-maximal inhibitory dilution (IC50) represents the 1324 
plasma dilution to inhibit 50 % of the infection of 293T-ACE2 cells by recombinant viruses bearing 1325 
the SARS-CoV-2 S glycoproteins.  1326 
 1327 
Microneutralization assay 1328 
A microneutralization assay for SARS-CoV-2 serology was performed as previously described 1329 
(Amanat et al., 2020). Experiments were conducted with the SARS-CoV-2 USA-WA1/2020 virus 1330 
strain (obtained from BEI resources). One day prior to infection, 2x104 Vero E6 cells were seeded 1331 
per well of a 96 well flat bottom plate and incubated overnight at 37°C under 5% CO2 to permit 1332 
cell adherence. Titrated antibody concentrations were performed in a separate 96 well culture 1333 
plate using MEM supplemented with penicillin (100 U/mL), streptomycin (100 mg/mL), HEPES, 1334 
L-Glutamine (0.3 mg/mL), 0.12% sodium bicarbonate, 2% FBS (all from Thermo Fisher Scientific) 1335 
and 0.24% BSA (EMD Millipore Corporation). In a Biosafety Level 3 laboratory (ImPaKT Facility, 1336 
Western University), 103 TCID50/mL of SARS-CoV-2 USA-WA1/2020 live virus was prepared in 1337 
MEM + 2% FBS and combined with an equivalent volume of respective antibody dilutions for one 1338 
hour at room temperature. After this incubation, all media was removed from the 96 well plate 1339 
seeded with Vero E6 cells and virus:antibody mixtures were added to each respective well at a 1340 
volume corresponding to 600 TCID50 per well and incubated for one hour further at 37°C. Both 1341 
virus only and media only (MEM + 2% FBS) conditions were included in this assay. All 1342 
virus:plasma supernatants were removed from wells without disrupting the Vero E6 monolayer. 1343 
Each antibody concentration (100 µL) was added to its respective Vero E6-seeded well in addition 1344 
to an equivalent volume of MEM + 2% FBS and was then incubated for 48 hours. Media was then 1345 
discarded and replaced with 10% formaldehyde for 24 hours to cross-link Vero E6 monolayer. 1346 
Formaldehyde was removed from wells and subsequently washed with PBS. Cell monolayers 1347 
were permeabilized for 15 minutes at room temperature with PBS + 0.1% Triton X-100, washed 1348 
with PBS and then incubated for one hour at room temperature with PBS + 3% non-fat milk. An 1349 
anti-mouse SARS-CoV-2 nucleocapsid protein (Clone 1C7, Bioss Antibodies) primary antibody 1350 
solution was prepared at 1 mg/mL in PBS + 1% non-fat milk and added to all wells for one hour 1351 
at room temperature. Following extensive washing with PBS, an anti-mouse IgG HRP secondary 1352 
antibody solution was formulated in PBS + 1% non-fat milk. One-hour post-incubation, wells were 1353 
washed with PBS, SIGMAFAST OPD developing solution (Millipore Sigma) was prepared as per 1354 
manufacturer’s instructions and added to each well for 12 minutes. Dilute HCl (3.0 M) was added 1355 
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to quench the reaction and the optical density at 490 nm of the culture plates was immediately 1356 
measured using a Synergy LX multi-mode reader and Gen5 microplate reader and imager 1357 
software (BioTek). 1358 
 1359 
Cell-to-cell fusion assay 1360 
To assess cell-to-cell fusion, 2 × 106 293T cells were co-transfected with plasmid expressing HIV-1361 
1 Tat (1µg) and a plasmid expressing SARS-CoV-2 Spike (4 µg) using the calcium phosphate 1362 
method. Two days after transfection, Spike-expressing 293T (effector cells) were detached with 1363 
PBS-EDTA 1mM and incubated for 1 hour with indicated amounts of CV3-1 and/or CV3-25 NAbs 1364 
at 37oC and 5% CO2. Subsequently, effector cells (1 × 104) were added to TZM-bl-ACE2 target 1365 
cells that were seeded at a density of 1 × 104 cells/well in 96-well luminometer-compatible tissue 1366 
culture plates 24 h before the assay. Cells were co-incubated for 6 h at 37°C and 5% CO2, after 1367 
which they were lysed by the addition of 40 μl of passive lysis buffer (Promega) and one freeze-1368 
thaw cycles. An LB 941 TriStar luminometer (Berthold Technologies) was used to measure the 1369 
luciferase activity of each well after the addition of 100 μl of luciferin buffer (15 mM MgSO4, 15 1370 
mM KH2PO4 [pH 7.8], 1 mM ATP, and 1 mM dithiothreitol) and 50 μL of 1 mM d-luciferin potassium 1371 
salt (ThermoFisher Scientific). 1372 
 1373 
Antibody dependent cellular cytotoxicity (ADCC) assay 1374 
For evaluation of anti-SARS-CoV-2 ADCC activity, parental CEM.NKr CCR5+ cells were mixed 1375 
at a 1:1 ratio with CEM.NKr-Spike cells. These cells were stained for viability (AquaVivid; Thermo 1376 
Fisher Scientific) and a cellular dye (cell proliferation dye eFluor670; Thermo Fisher Scientific) 1377 
and subsequently used as target cells. Overnight rested PBMCs were stained with another 1378 
cellular marker (cell proliferation dye eFluor450; Thermo Fisher Scientific) and used as effector 1379 
cells. Stained effector and target cells were mixed at a 10:1 ratio in 96-well V-bottom plates. 1380 
Titrated concentrations of CV3-1 and CV3-25 mAbs were added to the appropriate wells. The 1381 
plates were subsequently centrifuged for 1 min at 300xg, and incubated at 37°C, 5% CO2 for 5 1382 
hours before being fixed in a 2% PBS-formaldehyde solution.  1383 
ADCC activity was calculated using the formula: [(% of GFP+ cells in Targets plus Effectors)-(% 1384 
of GFP+ cells in Targets plus Effectors plus antibody)]/(% of GFP+ cells in Targets) x 100 by 1385 
gating on transduced live target cells. All samples were acquired on an LSRII cytometer (BD 1386 
Biosciences) and data analysis performed using FlowJo v10 (Tree Star). 1387 
 1388 
Antibody dependent cellular phagocytosis (ADCP) assay 1389 
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The ADCP assay was performed using CEM.NKr-Spike cells as target cells that were 1390 
fluorescently labelled with a cellular dye (cell proliferation dye eFluor450). THP-1 cells were used 1391 
as effector cells and were stained with another cellular dye (cell proliferation dye eFluor670). 1392 
Stained target and effector cells were mixed at a 5:1 ratio in 96-well U-bottom plates. Titrated 1393 
concentrations of CV3-1 and CV3-25 mAbs were added to the appropriate wells. After an 1394 
overnight incubation at 37 °C and 5% CO2, cells were fixed with a 2% PBS-formaldehyde solution. 1395 
Antibody-mediated phagocytosis was determined by flow cytometry, gating on THP-1 cells that 1396 
were double-positive for efluor450 and efluor670 cellular dyes. All samples were acquired on an 1397 
LSRII cytometer (BD Biosciences) and data analysis performed using FlowJo v10 (Tree Star). 1398 
 1399 
smFRET imaging of S on SARS-CoV-2 VLPs (S-MEN particles) 1400 
S-MEN coronavirus-like particles carrying SARS-CoV-2 spikes were prepared similarly as 1401 
previously described (Lu et al., 2020). The peptides tags-carrying spike plasmid (pCMV-S Q3-1 1402 
A4-1: Q3 - GQQQLG; A4 - DSLDMLEM) was used to make S-MEN coronavirus-like particles. 1403 
Plasmids encoding wildtype pCMV-S, dual-tagged pCMV-S Q3-1 A4-1, pLVX-M, pLVX-E, and 1404 
pLVX-N were transfected into 293T cells at a ratio of 20:1:21:21:21. Using this very diluted ratio 1405 
of tagged-S vs. wildtype S, the vast majority of S-MEN particles carry wildtype spikes. For the rest 1406 
of the virus particles containing tagged S, more than 95 % S trimers will have one dual-tagged 1407 
protomer and two wildtype protomers within a trimer. Using this strategy, we generated S-MEN 1408 
particles with an average of one dual-tagged S protomer for conjugating FRET-paired 1409 
fluorophores among predominantly wildtype S trimers presented on VLP surface. S-MEN particles 1410 
were harvested 40 h post-transfection, filtered with a 0.45 µm pore size filter, and partially purified 1411 
using ultra-centrifugation at 25,000 rpm for 2 h through a 15 % sucrose cushion made in PBS. S-1412 
MEN particles were then re-suspended in 50 mM pH 7.5 HEPES buffer, labeled with Cy3B(3S) 1413 
and Cy5 derivative (LD650-CoA) and purified through an optiprep gradient as previously 1414 
described (Lu et al., 2019; Lu et al., 2020; Munro et al., 2014)  1415 
smFRET images of S-MEN particles was acquired on a home-built prism-based total internal 1416 
reflection fluorescence (TIRF) microscope, as described previously (Lu et al., 2020). smFRET 1417 
data analysis was performed using MATLAB (MathWorks)-based customized SPARTAN software 1418 
package (Juette et al., 2016). The conformational effects of 50 ug/ml CV3-1 and CV3-25 1419 
antibodies on SARS-CoV-2 spike were tested by pre-incubating fluorescently labeled viruses for 1420 
60 mins at 37 oC before imaging in the continued presence of the antibodies. During smFRET 1421 
imaging, fluorescently-labeled S-MEN particles were monitored for 80 seconds, where 1422 
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprintthis version posted March 22, 2021. ; https://doi.org/10.1101/2021.03.22.436337doi: bioRxiv preprint 
54 
 
fluorescence from Cy3B(3S) and LD650-CoA labeled on S-MEN particles was recorded 1423 
simultaneously at 25 frames per second for 80 seconds. Donor (Cy3B(3S)) and acceptor (LD650-1424 
CoA) fluorescence intensity traces were extracted after subtracting background signals and 1425 
correcting cross-talks. The energy transfer efficiency (FRET) traces were generated from 1426 
fluorescence intensity traces, according to FRET= IA/(γID+IA), where ID and IA are the fluorescence 1427 
intensities of donor and acceptor, respectively, γ is the correlation coefficient compromising the 1428 
discrepancy in quantum yields and detection efficiencies of two fluorophores. FRET is sensitive 1429 
to changes in distances between the donor and the acceptor over time, ultimately translating into 1430 
the conformational profiles and dynamics of S on S-MEN particles. S-MEN particles that contain 1431 
incomplete FRET-paired fluorophores or more than one FRETing pairs of donor and acceptor on 1432 
a single virus particle were automatically filtered from virus pools for further analysis. FRET traces 1433 
of fluorescently-labeled S-MEN particles which meet the criteria of sufficient signal-to-noise ratio 1434 
and anti-correlated fluctuations in donor and acceptor fluorescence intensity are indicative of live 1435 
molecules. These FRET traces, indicated the number of traces in Figure 3, were then compiled 1436 
into FRET histograms in Figure 3. Each FRET histogram was fitted into the sum of four Gaussian 1437 
distributions in Matlab, where each Gaussian distribution represents one conformation and the 1438 
area under each Gaussian curve estimates the occupancy. 1439 
 1440 
Quantification and Statistical Analysis 1441 
Data were analyzed and plotted using GraphPad Prism software (La Jolla, CA, USA). Statistical 1442 
significance for pairwise comparisons were derived by applying non-parametric Mann-Whitney 1443 
test (two-tailed). To obtain statistical significance for survival curves, grouped data were 1444 
compared by log-rank (Mantel-Cox) test. To obtain statistical significance for grouped data we 1445 
employed 2-way ANOVA followed by Dunnett’s or Tukey’s multiple comparison tests.  1446 
p values lower than 0.05 were considered statistically significant. P values were indicated as ∗, p 1447 
< 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001; ∗∗∗∗, p < 0.0001. 1448 
 1449 
Schematics 1450 
Schematics for showing experimental design in figures were created with BioRender.com. 1451 
  1452 
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